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Abstract 
Therapeutic drug monitoring (TDM) is the measurement of drugs and/or metabolites in 
biological samples to guide therapy. TDM for antipsychotic drug therapy in schizophrenia 
treatment is well-established if adherence is in doubt and in dose optimisation.  
The antipsychotic quetiapine has a short plasma half-life and no clear reference range for 
clinical response. Three quetiapine metabolites, N-desalkylquetiapine, O-desalkylquetiapine 
and 7-hydroxyquetiapine, were investigated in routine plasma TDM samples to determine 
whether they provide useful information to assess quetiapine exposure. Compared to median 
plasma quetiapine concentrations, N-desalkylquetiapine, O-desalkylquetiapine and 7-hydroxy-




, respectively. All 
metabolites showed greater correlation to dose than quetiapine itself; dose-related plasma 
concentrations have been presented to aid future results interpretation.  
Blood sampling is invasive; hence, oral fluid was investigated as an alternative matrix. A clinical 
study was undertaken to investigate the relationship between analyte concentrations in oral fluid 
samples collected using different oral fluid collection devices [Greiner Bio-One (GBO; in-mouth 
buffered collected system), and Thermo Oral-Eze] and in plasma. Existing plasma LC-M/MS 
methods were combined, and sample preparation modified to be suitable for acidified (buffered) 
oral fluid samples. The methods were assessed to ensure they were fit-for-purpose.  
Relationships between plasma and oral fluid concentrations of clozapine and norclozapine were 
poor, and no better than results obtained using unstimulated oral fluid collected via the drool 
method. Median concentrations of all analytes were lower in the GBO samples than Oral-Eze 
samples; however, clozapine and norclozapine concentrations in samples collected using the 
proprietary devices were approximately twice the concentration measured in samples collected 
by the drool method, as a ratio to plasma concentrations. Concentration differences are possibly 
related to differing salivary stimulation during sample collection. A positive finding was a patient 
who had become non-adherent to clozapine was identified from oral fluid as well as plasma 
analysis.  
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Chapter 1.  Introduction 
1.1 Therapeutic drug monitoring 
During the course of routine drug therapy, the aim is to ensure that the correct amount of drug is 
present within the patient’s system to provide a beneficial outcome and reduce the risk of 
adverse drug reactions. Optimising the treatment regime to the individual can ensure the drug is 
given a fair trial, rather than the treatment being altered unnecessarily in cases where the dose 
was not suitable. For many drugs there are established doses at which a clinical response is 
predicted and where toxicity is unlikely, such as in the case of paracetamol where taking a 
standard dose predicts therapeutic benefit. However, for some drugs there is a poor correlation 
between administered dose and therapeutic benefit. Often this poor correlation is related to the 
mode of administration and distribution to the active site; for example, in muscle pain, topical 
pain relief applied directly to the site of pain may be fastest way to reduce pain in that area, but 
this would not be an appropriate form of administration for drugs that act on other organs. Drugs 
that are active in the brain, for example, must usually circulate in the blood and then distribute 
across the blood-brain barrier before reaching the site of activity and therefore there are many 
factors that can lead to large between-patient variation in response at a given dose.  
Factors that can affect how much of an oral dose is present in the bloodstream and thus 
circulates within the body include oral bioavailability (i.e. the proportion of the administered dose 
that enters the systemic circulation), the rate of liberation of the drug from the formulation, and 
the plasma half-life of the drug, which is affected by the individual’s metabolic capacity for the 
drug in question. Adherence to the treatment regime is also an important factor with oral therapy 
and may manifest as partial adherence where some of the prescribed dosage is taken, but not 
all or not consistently, or total non-adherence where the patient does not take any of the 
prescribed medication for a period of time. 
Therapeutic drug monitoring (TDM) is a method by which the concentration of a drug is 
measured within a clinical sample, often whole blood or plasma. For TDM to be of clinical value 
there must be a correlation between the clinical effect and the concentration of the drug and any 
active metabolite(s) in the relevant matrix, i.e. a reference range for therapeutic benefit, as well 
as a concentration above which there is an increased risk of toxicity. TDM is therefore used to 
assess adherence, establish dose adequacy and minimise the risk of toxicity.  
 Page 16 
TDM is used within many fields, one of which is psychiatry. Often in this field medication is 
essential and can provide many benefits, both medical and economic, when the therapy is 
successful (Hiemke et al., 2011). The main requirement for TDM within this field is due to the 
sometimes 20-fold variation in dose required to attain equivalent plasma concentrations 
between patients, so that after changes in co-prescribed medications, or taking into account 
pharmacogenetics factors, a suitable dose can be administered to each patient to achieve the 
highest possible chance of response with the lowest risk of toxicity (Hiemke et al., 2011).  
Drugs in the systemic circulation are commonly bound to plasma proteins, such as albumin or 
alpha-1 acid glycoprotein, depending on the physiochemical properties of the compound in 
question. There are believed to be a finite number of plasma protein binding sites, and therefore 
analytes can be displaced or compete for active sites, meaning the amount of analyte bound to 
plasma proteins can differ for the same drug in different individuals, or in the same individual 
following changes to co-prescribed medications (Patsalos and Berry, 2013); disease states 
such as acute kidney failure can also alter circulating protein concentrations (Patsalos and 
Berry, 2013).  
Since the site of activity of centrally-acting drugs is through the blood-brain barrier, the portion 
of drug that is free (unbound) in plasma is that which is able to cross this membrane and hence 
this may sometimes be classified as the ‘active’ fraction. In general TDM undertaken on plasma 
will quantify the total, rather than free, fraction and hence the concentrations may not always be 
truly representative of activity if the concentrations of binding proteins or binding sites change 
between samples. Quantifying the free fraction requires relatively complex sample preparation 
techniques, which are often more expensive and therefore less utilised within routine TDM than 
measuring total drug concentrations. In addition, the assay methods used are likely to alter the 
free fraction leading to potentially misleading results.  
Alternative means to estimate the free fraction can include the use of oral fluid (OF). Oral fluid is 
a matrix formed mainly from saliva, the largely water-based fluid secreted by the salivary 
glands, but also includes proteins (including enzymes, albumin and mucin), electrolytes and cell 
debris. The portion of drug that enters the salivary ducts and is secreted into oral fluid has been 
claimed to represent the free fraction for some drugs including anticonvulsant drugs (Patsalos 
and Berry, 2013). Another advantage of oral fluid is that collection is non-invasive compared to 
plasma samples, since collection does not require venepuncture. 
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1.2 Antipsychotic drugs 
Antipsychotic drugs (also known as neuroleptic drugs) are the mainstay of the treatment of 
schizophrenia, a disease that affects some 2 % of the population. Schizophrenia generally 
arises in early adulthood, with the onset usually being earlier and with greater severity and 
higher prevalence in males compared to females (Flanagan, 2006). Overall the symptoms can 
be divided into three broad categories: positive symptoms, which include delusions, 
hallucinations, and impaired communication; negative symptoms such as social withdrawal and 
lack of drive; and cognitive dysfunction, which affects insight, memory and reasoning. 
First generation (‘typical’) antipsychotics (FGAs), such as chlorpromazine, that were introduced 
in the early 1950s, were found to relieve some of the positive symptoms of schizophrenia 
including hallucinations, delusions and hyperactivity (Flanagan, 2006). However, these 
medications are generally not as effective against negative or cognitive symptoms and can 
cause a high prevalence of side effects especially those known as extra-pyramidal side effects 
(EPS; Taylor et al., 2015). EPS are repetitive involuntary movements of muscles or limbs similar 
to those seen in Parkinson disease, and can progress to tardive dyskinesia where the 
involuntary movements become more pronounced and can persist even after discontinuation of 
the medication, causing lifelong disability.  
Development of second generation (‘atypical’) antipsychotics (SGAs) such as clozapine gave 
drugs that were effective against both the positive and negative symptoms as well as improving 
cognitive impairment through much broader neurotransmitter antagonism (Flanagan, 2006). 
These drugs generally display lower risk of EPS than FGAs, however they have been 
associated with an increased risk of raised plasma prolactin, other biochemical abnormalities, 
sexual dysfunction and weight gain (Taylor et al., 2015). Newer antipsychotics, such as 
aripiprazole, have been developed to act as both antagonists and partial agonists on 
neurotransmitter activity, and some evidence suggests aripiprazole is as effective as other 
SGAs whilst causing fewer side effects (Taylor et al., 2015). 
Treatment-resistant schizophrenia (TRS) is the term used to denote a form of the illness where 
at least two antipsychotics have been trialled without benefit; clozapine is the only antipsychotic 
drug that has proven benefit in these cases (Taylor, 2017). Due to the nature of schizophrenia, 
adherence to antipsychotic drug medication regimes can be low. The role of TDM in guiding 
treatment with SGAs is well-established if adherence is in doubt and in dose optimisation, 
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especially for clozapine, and may be useful in dose adjustment with quetiapine, amisulpride and 
olanzapine (Hiemke et al., 2011).  
Antipsychotic drugs are commonly prescribed for oral use, either as a normal (immediate) 
release tablet (IR), an orodispersible medication, or as an extended/modified release (ER) 
formulation. In ER formulations a coating is applied that is resistant to digestion/dissolution in 
the gastrointestinal tract and therefore the drug is liberated more slowly than in normal release 
formulations, with the aim of giving an extended duration of drug action. There are also some 
medications that are available as an intra-muscular injection, which can be given weekly, 
2-weekly, or monthly, and release the medication slowly into the systemic circulation. 
Commonly, such formulations are used in patients that are poorly adherent to a daily or bi-daily 
oral treatment regime. 
In general SGAs are basic lipophilic drugs, as this enables them to cross the blood-brain barrier 
to the site of activity, and often they are significantly plasma protein bound (Table 1.1), although 
there are exceptions, most notably amisulpride and sulpiride, which are much more water 




Table 1.1: Physiochemical properties of analytes of interest 








Fraction bound to 
plasma protein* 
Major plasma metabolites 
Amisulpride 11 - 27 9.4 1.10 0.17 Nil 
Aripiprazole 60 - 90 7.6 4.70 0.99 Dehydroaripiprazole 
Clozapine 6 - 17 7.6 3.23 0.95 
N-Desmethylclozapine 
(Norclozapine) 
Fluoxetine 24 - 72 9.5 4.05 0.94 
N-Desmethylfluoxetine 
(Norfluoxetine) 
Olanzapine 21 - 54 7.4 1.7 (pH7) 0.93 Nil 
Quetiapine 2.7 - 9.3 6.8 4.31 0.83 N-Desalkylquetiapine 
Risperidone 2 - 20 8.2 3.49 0.90 9-Hydroxyrisperidone 
Sulpiride 4 - 11 9.0 0.57 0.40 Nil 
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1.2.1 Clozapine 
Clozapine is the only drug with proven efficacy in TRS, but is associated with significant toxicity 
in normal use. Clozapine was initially developed in the 1960s, but some 2 % of patients suffered 
from unexplained agranulocytosis (life-threatening reduction in white blood cells), and hence the 
drug was withdrawn from clinical use. No drug has yet been developed that has shown the 
success of clozapine in TRS, and therefore in the 1990s it was relicensed under strict provisions 
that all patients undergo routine haematological monitoring to identify cases of impending 
agranulocytosis. Agranulocytosis generally presents within the first few months of therapy, 
hence new patients are monitored weekly for the first few months, with the regularity decreasing 
to monthly for the remainder of therapy as the risk of developing agranulocytosis stabilises 
(Bleakley and Taylor, 2013). 
Clozapine is very toxic in someone who has either not taken it before, or who has lost tolerance 
to the drug; a routine daily dose of clozapine can kill a clozapine-naïve patient or someone who 
has not taken the medication for a few days (Bleakley and Taylor, 2013), hence therapy is 
initiated via cautious dose titration. Clozapine can rarely cause myocarditis and 
cardiomyopathy, possibly due to direct toxicity to the heart tissue or through an immune 
response, which may prove fatal if not diagnosed in life (Khan et al., 2017). On the other hand, 
gastrointestinal (GI) toxicity is very common during clozapine therapy, generally in the form of 
GI hypomotility (e.g. constipation) that if not monitored and treated can lead to severe 
symptoms, including faecal vomiting and GI rupture, which can prove fatal (Bleakley and Taylor, 
2013). Other side effects include an increased risk of convulsions at higher doses or plasma 
concentrations, hypersalivation, and biochemical abnormalities, as mentioned above. 
Clozapine is metabolised primarily to an N-demethylated product N-desmethylclozapine 
(norclozapine) via cytochrome P450 (CYP) 1A2, CYP 3A4 and CYP 2D6. CYP 2D6 and CYP 
3A4 have a number of genetic polymorphisms that cause wide between-patient variability in 
enzyme activity. The activity of CYP 1A2 also displays variability between patients, and is 
affected by a number of factors including cigarette (and cannabis) smoking and co-prescribed 
medications. Polycyclic aromatic hydrocarbons inhaled when smoking induce the activity of 
CYP 1A2, meaning that patients who smoke require a higher dose on average of clozapine than 
patients who do not smoke, and stopping smoking can cause the plasma clozapine 
concentration to increase dramatically unless the dose is cut. The antidepressant fluvoxamine 
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and antibiotic ciprofloxacin, as well as some other drugs, significantly inhibit CYP 1A2 activity 
and therefore addition of these drugs can cause clozapine plasma concentrations to increase 
leading to toxicity at a constant clozapine dose. Overall, variation of clozapine concentrations 
attained between different individuals for a given dose can vary up to 50-fold (Couchman et al., 
2010). As such, attaining the optimal therapeutic dose for individual patients can be very 
challenging; the use of TDM is therefore well established for this drug, especially during initial 
titration, at a change in dose or co-prescribed medication, and when the patient stops or starts 
smoking (Hiemke et al., 2011). 
1.2.2 Quetiapine 
Quetiapine is an SGA that is predominantly used in the treatment of schizophrenia and bipolar 
disorder (mania and depression); also, the ER formulation is used as an adjunct in patients with 
major depressive disorder in cases where antidepressant monotherapy has had a sub-optimal 
response (Al Jurdi et al., 2010; Anderson et al., 2009; El-Khalili et al., 2010; Ketter et al., 2016: 
Liebowitz et al., 2010; Mauri et al., 2016; McIntyre et al., 2009). Whilst not licensed for the 
indications, quetiapine is increasingly being shown to be effective in the treatment of anxiety 
and sleep disorders (Altamura et al., 2011; Baune et al., 2007; Kreys and Phan, 2015; 
Maneeton et al., 2016; Stein et al., 2011). 
Broadly, quetiapine is well tolerated and patients do not describe significant toxicity. However, 
quetiapine is linked to a risk of increased body weight and raised metabolic markers including 
plasma triglycerides with increasing prescribed dose (Zhornitsky et al., 2011). In overdose, 
plasma quetiapine concentrations were reported to be greater than 3000 µg/L, approximately 
10-times those suggested for therapeutic benefit, with reported symptoms of only tachycardia 
and somnolence (Hunfield et al., 2006). 
Quetiapine is metabolised mainly by CYP 3A4, with a contribution from both CYP 2D6 and 
CYP 3A5 (DeVane and Nemeroff, 2001), forming a number of metabolites. N-Desalkyl-
quetiapine (widely referred to as norquetiapine) is the major metabolite believed to be 
pharmacologically active in the treatment of depression and may mediate the antidepressant 
effect of quetiapine at least in part due to greater activity at receptor sites than the parent 
compound (Di Benedetto et al., 2012; Jensen et al., 2008; López-Muñoz and Alamo, 2013). 
7-Hydroxyquetiapine and 7-hydroxy-N-desalkylquetiapine may possess antipsychotic activity; 
however, they accumulate to much lower concentrations in plasma than quetiapine itself (Davis 
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et al., 2010; Fisher et al., 2012A; Li et al., 2004). There is a lack of data as to the plasma 
concentrations of quetiapine sulfoxide and quetiapine carboxylic acid attained during therapy, 
and neither are thought to display any pharmacological activity, although these compounds 
have been found in urine (Strickland et al., 2016; Winter et al., 2008).  
Quetiapine has a plasma half-life of around 7 hours, reaching maximum concentrations around 
1 hour after an oral dose (Figueroa et al., 2009), meaning twice-daily dosing is often required to 
maintain steady state plasma concentrations over the course of a day. The ER formulation aims 
to release quetiapine over the course of 20 hours with maximal concentrations at 5 hours after 
an oral dose, reaching lower maximal concentration, but giving equivalent overall exposure 
compared to the IR formulation (Bui et al., 2013; Figueroa et al., 2009). As such, ER quetiapine 
can be given once-daily, at night, which may reduce daytime somnolence (Riedel et al., 2015). 
The plasma half-life is believed to be around 8 hours for 7-hydroxyquetiapine and 
7-hydroxy-N-desalkylquetiapine (Li et al., 2004), with N-desalkylquetiapine around 11 hours 
(Winter et al., 2008). Due to the longer half-life of N-desalkylquetiapine, compared to quetiapine 
and the other metabolites, plasma concentrations are less affected by formulation or time that 
the sample was taken after dose, suggesting this could be a better marker than plasma 
quetiapine or other metabolite concentrations for assessing quetiapine exposure than 
measuring quetiapine itself (Fisher et al., 2012A). 
 
1.2.3 Other relevant drugs 
Olanzapine, amisulpride, risperidone and Paliperidone (±-9-hydroxyrisperidone) are SGAs for 
which plasma TDM is offered, and reference ranges associated with effective therapy have 
been suggested for these drugs (Hiemke et al., 2011). In addition, aripiprazole and sulpiride 
(commonly referred to as an FGA) are routinely analysed in plasma, although TDM is generally 
used only to assess adherence since a reference range for effective therapy is not firmly 
established and side effects are less severe.  
Finally, the antidepressant fluoxetine (Prozac) was included within the study due to the large 
number of prescriptions of this medication in children within the local mental health hospital, and 
concerns over adherence in this population (Nakonezny et al., 2010). 
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1.3 Methodology 
In order to get meaningful TDM results there must be a high degree of confidence that the 
reported result is indicative of the circulating drug or metabolite concentrations. In order to 
achieve this, the methodology that is used to quantify the analyte(s) in question must be shown 
to be fit-for-purpose; that it is sensitive, selective and accurate enough for the concentrations to 
be measured in the samples available (FDA/CDER, 2001). There are a number of possible 
steps involved in the quantification of analytes from a given matrix, and modifying the 
application of each step enables development of a method that is more or less selective and 
sensitive depending on individual need.  
Sample preparation is the means by which analytes within a sample are prepared for detection 
and quantification. Sample preparation can range from simple protein-precipitation, which can 
lead to a number of interferences being present during an analysis, to more complex forms of 
sample clean-up such as solid-phase extraction and liquid-liquid extraction (LLE) that are more 
labour-intensive, but usually lead to cleaner extracts and therefore more specificity and 
selectivity. LLE can be used to make an analytical method very selective since the choice of 
extraction solvent and pH can be optimised to the analyte(s) of interest in order to exclude 
interferences, and when coupled to strong-cation exchange (SCX) chromatography the 
selectivity and robustness of methods for basic  (proton-accepting) analytes can be enhanced 
(Flanagan et al., 2001).  
Chromatography is commonly used to separate analytes within an extract in order improve 
selectivity and hence, minimise interferences during the analysis. Separation is typically 
undertaken by the use of a stationary phase within a column that contains an active group that 
binds analytes flowing through the column following injection into the mobile phase. Binding 
affinity depends on the analyte in question as well as the selection of mobile phase and 
stationary phase, where modifying each parameter can affect the separation of the analyte from 
any  interferences present in the extract. The selection of mobile phase is also determined by 
the type of detection that is selected; most commonly detection is by mass-spectrometry, where 
the mobile phase flows into a source that ionises analytes within the column effluent and uses 
mass and ionisation as a means of investigating the content of the flow at a point in time. A 
number of methods for quantifying SGA concentrations attained during therapy have been 
published, many of which use liquid chromatography (LC) with mass spectrometry (MS) (Patteet 
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et al., 2015). Use of tandem mass spectrometry (MS/MS), in which a precursor ion of specified 
mass-to-charge ratio (m/z) is fragmented under defined conditions to give product ion(s) of 
different m/z, can provide additional selectivity and hence sensitivity. Addition of a stable 
isotope-labelled internal standard (IS) to the sample prior to extraction helps compensate for 
extract-to-extract variations during sample preparation and analysis. Optimising the sample 
preparation, separation and detection can enable faster analysis times to aid sample 
throughput, thereby ensuring the results are available as soon as possible to the clinical team. 
Application of method selection techniques has enabled development of a selective method 
capable of analysing a number of SGAs, as well as aripiprazole and sulpiride, and their major 
plasma metabolites in a single plasma sample (Fisher et al., 2013B), and has been modified to 
include three additional quetiapine metabolites (N-desalkylquetiapine, O-desalkylquetiapine and 
7-hydroxyquetiapine; Fisher et al., 2012B). 
1.4 Alternative Samples 
Plasma is the traditional sample type for antipsychotic TDM purposes, and such measurements 
are the basis of most reference ranges (Hiemke et al., 2011). However, obtaining venous blood 
is an invasive procedure. Patients may be unwilling to provide samples or there may be difficulty 
obtaining such a sample, for example if a vein collapses, and there are additional 
considerations in the case of children. Collection of a blood sample is ideally only undertaken if 
there is no diagnostic alternative, and in the case of clozapine the requirement for regular 
haematological monitoring is a common reason that patients refuse treatment with the drug 
(Gee et al., 2014). However, advances in haematological monitoring using capillary (finger-
prick) samples may in the future minimise the requirement for venepuncture in clozapine 
patients. 
Alternative matrices to plasma, such as oral fluid and capillary blood, enable a sample to be 
taken from patients less invasively than by venepuncture. However, prior to implementation a 
correlation must be shown between analyte concentrations in the matrix of choice and clinical 
response, often established through a correlation to plasma concentrations (Fisher et al., 
2013A; Patsalos and Berry, 2013; Goosen et al., 2003). Oral fluid has been well proven as a 
matrix of choice for TDM of some (acidic) drugs such as anticonvulsants (Patsalos and Berry, 
2013), but there is little or no evidence that implementation of alternative matrices for 
antipsychotic TDM is feasible (Langman et al., 2007; Patteet et al., 2016). 
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Previous work using the drool method (unstimulated pooling of oral fluid in the mouth and spit 
into a tube) to collect samples from patients prescribed SGAs showed that there was a 
relationship between plasma and oral fluid concentrations of amisulpride, clozapine, quetiapine 
and risperidone (Fisher et al., 2013A). However, the correlations to plasma concentrations were 
low (R
2
 = 0.3-0.7), suggesting that whilst oral fluid analysis is feasible, the possibility of using 
oral fluid collected by this method to replace plasma for antipsychotic TDM was remote. 
One possible reason for the poor correlations between plasma and oral fluid concentrations in 
this latter study was the use of unstimulated oral fluid, which may be susceptible to between-
patient and between-collection variations in salivary pH and flow rate, variables that are thought 
to affect oral fluid concentrations of basic drugs (Aps and Martens, 2005; Drummer, 2008; 
Patsalos and Berry, 2013). Investigation of stimulated collection methods, including one that 
utilises a buffer held in the mouth to reduce variation in oral cavity pH during sample collections, 
may minimise the variability in the plasma:oral fluid relationship and thus facilitate use of oral 
fluid for TDM of basic drugs such as SGAs. 
1.5 Aims for the thesis 
Firstly, this work aims to extend previous work (Fisher et al., 2013A) investigating whether 
measuring three quetiapine metabolites (N-desalkylquetiapine, O-desalkylquetiapine and 
7-hydroxyquetiapine) enhances the value of quetiapine TDM. This will be in the form of an audit 
of reported analyte concentrations from plasma samples sent to the Toxicology Unit, King’s 
College Hospital (Viapath), for routine quetiapine TDM since September 2009, extending the 
dataset further than 2012 when the previous audit was completed. 
Secondly, the use of two commercial oral fluid collection devices will be investigated for 
applicability in antipsychotic TDM. The devices of interest are the Greiner Bio-One (GBO) 
collection device that uses an in-mouth buffered solution, and the Thermo Oral-Eze collection 
device that uses an adsorbent collection pad held against the cheek.  
Plasma LLE-LC-MS/MS methods (Fisher et al., 2013B; Fisher et al., 2012B) will be combined to 
allow analysis of all relevant analytes a single sample, including clozapine and norclozapine, 
and fluoxetine and N-desmethylfluoxetine (norfluoxetine). Once the detection has been 
optimised the sample preparation step will be investigated in order to develop an analytical 
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method to quantify the relevant analytes in the collection fluid from the two oral fluid collection 
devices.  
Once developed, the methods will be assessed to ensure they are fit-for-purpose. 
Finally, the methods will be used to quantify the analyte concentrations in samples collected 
using the oral fluid devices and in plasma from patients prescribed clozapine, following 
application to and achievement of ethics approval (Appendix A). Full sample sets will be 
collected from patients, first the Oral-Eze sample, followed by the GBO sample, and then blood 
will be collected to separate and store plasma. The analyte concentrations in each matrix from 
the sample sets will be quantified, patient demographics and dosage information collated, and 
the results will be studied to establish if samples collected using either of these devices display 
adequate predictive capacity to replace plasma analysis for TDM of clozapine and other basic 
drugs. 
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Chapter 2.  TDM of quetiapine metabolites  
2.1 Introduction 
TDM for quetiapine is recommended in patients that are not responding to the medication, or if 
there are changes to co-prescribed medication (Hiemke et al., 2011), especially when adding or 
removing drugs that may alter quetiapine plasma concentrations (e.g.. CYP 3A4 inducers, such 
as carbamazepine). There is no firm reference range for quetiapine, at least in part due to the 
large variability in quetiapine plasma concentrations observed in therapy (Sparshatt et al., 
2011). Quetiapine exposure varies widely between patients; in one study quetiapine exposure 
(presented as dose-corrected plasma quetiapine concentration) varied 238-fold between 
samples (Hasselstrøm and Linnet, 2004). One possible explanation for this is between-patient 
variability in CYP activity combined with possible effects of age, sex, and/or co-prescribed 
medication on quetiapine metabolism. Co-prescription of drugs that affect the activity of relevant 
CYPs and of proteins such as P-glycoprotein (PGP) that influence drug transport across 
membranes, such as inhibitors, inducers or competitive substrates, may affect the plasma 
quetiapine concentration at a constant quetiapine dose.  
Whilst there are some published reports on the effect of variables such as age, sex and 
co-prescribed medication on the plasma quetiapine concentrations attained during therapy 
(Aicchorn et al., 2006; Bakken et al., 2011; Castberg et al., 2007; Handley et al., 2013; 
Hasselstrøm and Linnet, 2004; Isbister et al., 2007; Ostad Haji et al., 2013; Wittmann et al., 
2010; Wong et al, 2001) little information is available regarding the relevance and predicted 
concentrations of other quetiapine metabolites that are known to accumulate in plasma, 
especially for O-desalkylquetiapine and 7-hydroxyquetiapine (Figure 2-1).  
Preliminary work was undertaken to investigate the importance of the metabolites in interpreting 
quetiapine exposure (Fisher et al., 2012A), but this work included only a small cohort of patient 
samples leading to difficulty in establishing the significance of the variables studied. 
Measurement of quetiapine metabolites, especially N-desalkylquetiapine with its longer plasma 
half-life, may enable reference ranges for these compounds to be established thus giving 
greater insight into the clinical picture.  
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Figure 2-1: Summary of quetiapine metabolism 
Cytochrome P450 (CYP) enzyme believed to play a major role in the formation of each metabolite given, 
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2.1.1 Aims of the chapter 
The results and patient demographics from samples submitted for routine quetiapine TDM at 
the Toxicology Unit, King’s College Hospital (Viapath), 2009-2016 will be compiled and 
anonymised. Using this dataset, correlation and regression studies will be undertaken to 
investigate whether quantification of quetiapine metabolites might provide additional knowledge 
to aid clinical interpretation in quetiapine TDM. 
 
2.2 Materials and methods 
The results from plasma samples sent for routine plasma quetiapine TDM at the Toxicology 
Unit, King’s College Hospital (Viapath), from September 2009 to October 2016 were compiled 
from the clinical database, anonymised, and subjected to audit. Overdose samples, post-
mortem samples, or those querying plasma quetiapine concentrations in patients who were not 
prescribed the medication were excluded. Information given at the time of submitting samples 
for analysis was collated, and included age and sex of the patient, time and date of sample, 
time since last quetiapine dose (TSLD, h), prescribed quetiapine dose (mg/d), and formulation 
[IR or ER]. 
2.2.1 Analytical method 
Analysis was undertaken within the Toxicology Unit, King’s College Hospital (Viapath) by 
LC-MS-MS (Fisher et al., 2012B), and results were reported according to normal clinical 
practices. Plasma quetiapine, N-desalkylquetiapine, O-desalkylquetiapine and 7-hydroxy-
quetiapine were reported to the nearest 1 µg/L. Lower limits of quantitation were: quetiapine and 
N-desalkylquetiapine, 5 µg/L; O-desalkylquetiapine and 7-hydroxyquetiapine, 2 µg/L.  
2.2.2 Statistical methods 
Statistical analysis was undertaken using Excel Analyse-It (v2.30 Excel 12+) and SPSS 
(Statistics v23).  
Statistical tests were chosen according to normal practices for scientific methods (Peacock and 
Kerry, 2006). Normal distribution was tested by the Shapiro-Wilks test. If the data were found to 
be normally distributed (parametric), correlation was performed by the Pearson correlation and 
comparison of groups was undertaken by a t-test. If the data were non-normally distributed 
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(non-parametric), Spearman correlation and Mann Whitney U test for comparison of groups 
were used. Significance was determined at p<0.05. 
2.2.2.1 Regression analysis 
Regression analysis was undertaken to describe the influence of independent variables (i.e. 
patient age and sex, prescribed dose or sample time post dose) on a dependent variable (e.g. 
oral fluid analyte concentration).  A model was created with each relevant independent variable 
included, and the most non-significant independent variable removed sequentially until all 
remaining in the model were significant to p<0.01 (Peacock and Kerry, 2006). 
The model created expressed the relative impact of each significant (p < 0.01) independent 
variable (V) on the dependent variable (Y, Table 2.1): 




: degree of association between the observed result and that predicted by the model. 
- B: relationship between a change in the independent variable and change in dependent 
variable – for an increase in V of 1, the dependent variable Y will increase by B. The 95 % 
confidence intervals (CI) of B describe the spread of results. 
- Beta: magnitude of influence of V within the model predicting Y – this expresses the 
relevance of this independent variable to the dependant variable. 
The regression model can be summarised according to the equation: 
Y = (B1 x V1) + (B2 x V2) + Bc 
 

















 95 % CI Beta 
d







V1 B1 CI1 Beta1 p1 
V2 B2 CI2 Beta2 p2 
constant Bc CIc - pc 
a – correlation between observed and predicted result 
b – proportion of variance in the dependent variable that can be explained by applying the model, degree 
of association between observes and predicted results  
c – coefficient for predicting the dependent variable from the independent variable 
d – standardised coefficient to describe the magnitude of effect of each independent variable 
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The strength of the model, described by R and R
2
, explains the proportion of the dependent 
variability that can be predicted by the independent variables, and therefore describes the 
relevance of the model. 
2.2.3 Dataset creation 
Initial analyses were undertaken using the entire dataset. Analyte concentration (C) was 
corrected for dose giving plasma concentration per mg quetiapine prescribed daily (C/D).  
Samples where no quetiapine was detected in the plasma were analysed separately, and 
removed from a regression data subset. In addition, results from patients from whom multiple 
samples were received were averaged to give a single result per patient to reduce the possible 
effect of skew from any patient from whom multiple samples were received (Fisher et al., 
2012A). Using this subset, correlation and regression analysis was undertaken and metabolic 
ratio (MR) was calculated as plasma concentration of the metabolite divided by plasma 
quetiapine concentration.  
To investigate the impact of co-prescribed medications, it was assumed that where one or more 
medications other than quetiapine were listed on the request form that this corresponded to all 
medications prescribed. Therefore, a subset of results was formed that included only those 
results from patients where at least one medication was listed. Using this subset of data, the 
impact of individual co-prescribed medications investigated, using the group of results that did 
not list that relevant medication as a control group. 
2.3 Results 
There were 509 samples from 321 patients (175 male, 146 female; Table 2.2) with an overall 
median (range) age of 37 (13-86) yr.  
2.3.1 Summary of quetiapine concentrations  
The summary concentrations attained for the samples as well as the dose and time since last 
dose are given in Table 2.3. The relationship between plasma analyte concentration and dose 
was investigated and showed whilst there was a trend of an increase in plasma metabolite 
concentrations with increasing dose, this was not matched for quetiapine (Figure 2-2).  
Correcting the analyte concentrations for quetiapine dose (Table 2.4) reduced the variation in 





percentiles (C/D compared to C).  
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Minimum 15 13 
5
th
 Percentile 17 16 
25
th
 Percentile 27 28 
Median 36 39 
75
th
 Percentile 46 51 
95
th
 Percentile 60 65 
Maximum 73 86 
Mean 37 40 
SD 13 15 


















Minimum 5 5 2 2 25 8 
5
th
 Percentile 14 22 3 2 250 11 
25
th
 Percentile 59 77 8 4 400 12 
Median 124 133 14 7 600 13 
75
th
 Percentile 280 225 25 14 750 15 
95
th
 Percentile 679 380 51 38 1000 20 
Maximum 2980 621 157 118 2000 26 
Mean 228 161 19 12 601 14 
SD 300 113 19 14 262 3 
Not detected 33 26 41 94   
N 509 509 509 509 335 287 
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Figure 2-2: Quetiapine audit: Plasma analyte concentration and dose relationship 
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Table 2.4: Quetiapine audit: Summary dose-corrected analyte concentrations 
 
 








Minimum 0.01 0.03 0.003 0.002 
5
th
 Percentile 0.03 0.08 0.007 0.004 
25
th
 Percentile 0.11 0.17 0.016 0.006 
Median 0.20 0.25 0.024 0.012 
75
th
 Percentile 0.45 0.35 0.038 0.020 
95
th
 Percentile 1.01 0.51 0.071 0.053 
Maximum 3.89 1.74 0.207 0.213 
Mean 0.37 0.29 0.031 0.018 
SD 0.52 0.21 0.025 0.020 




Investigating the concentrations that were attained at a given dose is important in interpreting 
an individual result with regards to expected concentrations (Table 2.5) as it establishes a likely 
range of concentrations enabling outlying concentrations to be highlighted and compliance to be 
assessed.  
Plasma metabolite concentrations increased with increasing dose for the metabolites according 
to both the median and mean, however the plasma quetiapine concentrations were much more 
variable and did not show a steady increase with increasing dose. 
As to the samples in which an analyte was not detected (ND, Table 2.5), these were from 
patients prescribed doses across the entire dose range, rather than just lower doses, 
suggesting that non-adherence to treatment may be the underlying cause of these findings in 
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Table 2.5: Quetiapine audit: Plasma analyte concentrations by prescribed dose band. 















  Max Mean SD 
25-200 14 0 5 8 17 54 135 721 778 153 251 
225-350 44 6 7 14 43 79 124 578 875 142 186 
400-575 71 2 13 20 63 130 244 470 877 177 156 
600 84 4 7 10 48 105 264 772 1875 234 359 
650-750 48 0 40 41 93 128 236 557 671 185 154 
800-950 56 2 6 27 76 152 288 606 1126 233 218 














  Max Mean SD 
25-200 14 0 8 13 29 36 55 189 216 58 60 
225-350 44 4 8 19 53 86 114 384 460 109 103 
400-575 71 0 17 34 73 103 150 222 417 114 65 
600 84 5 32 54 99 136 196 291 404 155 82 
650-750 48 0 33 59 131 182 251 351 484 199 96 
800-950 56 2 51 92 167 223 281 367 477 230 87 














  Max Mean SD 
25-200 14 3 2 3 4 7 11 23 31 9 8 
225-350 44 6 2 2 5 9 11 26 36 10 8 
400-575 71 0 2 2 8 13 19 30 43 14 9 
600 84 5 2 5 7 11 21 49 96 18 17 
650-750 48 0 5 7 12 17 23 35 38 18 8 
800-950 56 2 5 6 13 18 32 58 104 24 18 














  Max Mean SD 
25-200 14 7 2 2 2 6 13 26 32 10 11 
225-350 44 16 2 2 3 4 7 13 17 6 4 
400-575 71 5 2 2 3 5 9 20 36 7 6 
600 84 13 2 2 3 6 13 31 74 10 13 
650-750 48 2 2 3 5 8 14 32 42 11 9 
800-950 56 5 2 3 5 11 20 40 61 15 13 
1000-2000 18 2 3 3 9 13 23 40 41 17 13 
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2.3.1.1 Quetiapine not detected 
Twenty-four samples were received that had plasma quetiapine <5 µg/L. Of these, 
N-desalkylquetiapine was present in 6 (range 5-26 µg/L), and only the sample with the highest 
N-desalkylquetiapine concentrations had O-desalkylquetiapine and 7-hydroxyquetiapine (2 and 
3 µg/L, respectively) present. Prescribed quetiapine dose was given in 9 cases, with a median 
(range) of 475 (300-800) mg/d. 
The results from all 24 samples were excluded from the final regression data subset.  
2.3.2 Influence of studied variables on the concentrations 
The final regression data subset contained 297 records (Table 2.6); dose was recorded in 180 
instances (25 to 2000 mg/d), formulation for 49 results (10 IR, 39 ER), and time since last dose 
for 150 records (118 were samples taken 10 to 15 hours post-dose, with 32 over 15 hours post-
dose). 
The MR was calculated for each of the metabolites. The results are summarised in Table 2.7.  
Median MR for N-desalkylquetiapine shows an overall one-to-one relationship to quetiapine, 
whereas the MR for O-desalkylquetiapine and 7-hydroxyquetiapine were 10-times and 20-times 
lower than quetiapine concentrations, respectively. 
To establish whether there was a relationship between analyte concentrations and dose, age, or 
between the metabolite and quetiapine plasma concentrations, the correlations between these 
parameters were investigated (Table 2.8).  
There was a significant relationship between the plasma concentration of each analyte and 
dose, although the correlations (0.23 to 0.56) were poor. There was also a significant correlation 
between the plasma metabolite concentrations (C and C/D) and plasma quetiapine 
concentration, the strongest correlation was to O-desalkylquetiapine and the weakest to 
N-desalkylquetiapine. In addition as age increased, dose significantly decreased, and there was 
a significant decrease in MR for 7-hydroxyquetiapine and N-desalkylquetiapine, and increase in 
quetiapine C/D. 
The relationship between the metabolites showed the pairs N-desalkylquetiapine/ 
O-desalkylquetiapine and O-desalkylquetiapine/7-hydroxyquetiapine had the strongest 
relationship, especially when corrected for dose (Table 2.9). 
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Minimum 5 5 2 2 25 8 
5
th
 Percentile 15 23 3 2 300 11 
25
th
 Percentile 66 77 9 5 400 12 
Median 131 142 16 8 600 13 
75
th
 Percentile 295 234 26 14 800 15 
95
th
 Percentile 636 383 54 38 900 20 
Maximum 2980 590 157 118 2000 26 
Mean 235 164 20 13 611 14 
SD 302 113 20 14 261 3 
Not detected 0 0 6 37   




Table 2.7: Quetiapine audit: Summary quetiapine metabolic ratio data 
 
 
Metabolic ratio (plasma concentration of metabolite / quetiapine) 
N-Desalkylquetiapine O-Desalkylquetiapine  7-Hydroxyquetiapine 
Minimum 0.03 0.012 0.007 
5
th
 Percentile 0.18 0.047 0.015 
25
th
 Percentile 0.50 0.076 0.033 
Median 0.99 0.103 0.050 
75
th
 Percentile 1.80 0.153 0.087 
95
th
 Percentile 4.89 0.264 0.200 
Maximum 17.38 1.667 0.833 
Mean 1.60 0.129 0.074 
SD 2.21 0.125 0.084 
N 297 291 260 
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Table 2.8: Quetiapine audit: Correlation between quetiapine concentration, dose and age for quetiapine 
and metabolites. 
Significance (p values) of Spearman correlation given in brackets; significant correlations highlighted in 
bold. 
 
Dependent variable * 
Factor, correlation and significance 
Quetiapine 
concentration, µg/L 
Dose, mg/d Age, years 
Quetiapine 
C - 0.23 (0.001) 0.03 (0.638) 
C/D - - 0.17 (0.021) 
N-Desalkylquetiapine 
C 0.47 (<0.001) 0.56 (<0.001) -0.09 (0.112) 
C/D 0.32 (<0.001) - -0.02 (0.748) 
MR - 0.15 (0.039) -0.13 (0.020) 
O-Desalkylquetiapine 
C 0.86 (<0.001) 0.43 (<0.001) -0.01 (0.891) 
C/D 0.77 (<0.001) - 0.12 (0.098) 
MR - 0.18 (0.013) -0.08 (0.169) 
7-Hydroxyquetiapine 
C 0.66 (<0.001) 0.32 (<0.001) -0.12 (0.044) 
C/D 0.54 (<0.001) - -0.03 (0.706) 
MR - 0.23 (0.003) -0.18 (0.004) 
Dose (mg/d) - - -0.19 (0.011) 
* Variables: C = analyte concentration (µg/L), C/D = analyte concentration corrected for dose (µg/L per 




Table 2.9: Quetiapine audit: Relationship between metabolites 
Significance (p values) of Spearman correlation given in brackets. 
 
Metabolite pairs 
Analyte correlation and significance * 
C C/D MR 
N-Desalkylquetiapine and O-Desalkylquetiapine 0.57 (<0.001) 0.64 (<0.001) 0.77 (<0.001) 
N-Desalkylquetiapine and 7-Hydroxyquetiapine 0.49 (<0.001) 0.25 (0.001) 0.75 (<0.001) 
O-Desalkylquetiapine and 7-Hydroxyquetiapine 0.71 (<0.001) 0.61 (<0.001) 0.80 (<0.001) 
* C = analyte concentration (µg/L), C/D = analyte concentration corrected for dose (µg/L per mg/d), MR = 
analyte concentration divided by quetiapine concentration. 
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The effect of sex, formulation and time since last dose on the plasma concentrations was also 
investigated (Table 2.10). The plasma concentrations of quetiapine and O-desalkylquetiapine 
were significantly different between results from 10-15 hours post-dose and over 15 hours post-
dose. There was a significant difference in N-desalkylquetiapine and O-desalkylquetiapine C/D 
between males and females, but there was not a significant difference in the prescribed dose 
between males and females. Formulation significantly affected quetiapine plasma concentration 
and C/D, O-desalkylquetiapine C/D, and the N-desalkylquetiapine MR. 
To specifically investigate the effect of the different quetiapine formulations on quetiapine 
exposure, the concentrations, C/D and MR of quetiapine and its metabolites were tabulated 
(Table 2.11). As the group comparison showed (Table 2.10), there was no large difference in 
the dose prescribed between the two groups. Quetiapine C and C/D did differ, however, being 
approximately one-third in the group prescribed IR compared to ER, likely due to the short 
half-life of quetiapine influencing the results markedly in those prescribed the IR formulation. 
 
Table 2.10: Quetiapine audit: Comparison for sex, formulation, and time since last dose for quetiapine and 
metabolites. 
Significant differences according to Mann Whitney U tests are highlighted in bold. 
 
Dependent variable * 
Factor, significance between groups 
Sex 
(M vs F) 
Formulation 
(IR vs ER) 
TSLD 
(10-15 h, > 15h) 
Quetiapine 
C 0.798 0.029 0.045 
C/D 0.130 0.011 0.106 
N-Desalkylquetiapine 
C 0.804 0.766 0.117 
C/D 0.011 0.402 0.355 
MR 0.687 0.044 0.076 
O-Desalkylquetiapine 
C 0.505 0.369 0.021 
C/D 0.007 0.048 0.154 
MR 0.219 0.052 0.181 
7-Hydroxyquetiapine 
C 0.241 0.245 0.122 
C/D 0.146 0.084 0.430 
MR 0.716 0.501 0.463 
Dose (mg/d) 0.149 0.398 0.286 
* Variables: C = analyte concentration (µg/L), C/D = analyte concentration corrected for dose (µg/L per 
mg/d), MR = analyte concentration divided by quetiapine concentration. 
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Table 2.11: Quetiapine audit: Effect of formulation on quetiapine metabolites 








 percentiles, as well as 
the mean and standard deviation. * indicates one sample not detected. Groups indicated as different by 
Mann Whitney U test (Table 2.10) highlighted bold. N=10, IR; N=39, ER. 
 
  








  Max Mean SD 
Quetiapine 
Dose 
IR 25 300 413 575 725 900 900 555 254 
ER 300 300 381 550 600 900 800 521 156 
TSLD 
IR 12 12 12 13 15 21 23 15 4 














IR 5 27 63 95 114 365 419 134 126 
ER 15 33 105 192 368 1001 1729 311 343 
N-Desalkyl-
quetiapine 
IR 8 41 113 128 145 286 360 141 91 
ER 41 62 89 127 197 316 406 159 91 
O-Desalkyl-
quetiapine* 
IR * 9 10 13 14 19 26 29 16 6 
ER 3 9 13 18 24 54 58 22 14 
7-Hydroxy-
quetiapine* 
IR * 2 3 4 5 8 26 29 9 9 





IR 0.08 0.09 0.13 0.18 0.23 0.60 0.76 0.24 0.20 
ER 0.03 0.06 0.22 0.46 0.77 1.63 3.04 0.61 0.65 
N-Desalkyl-
quetiapine 
IR 0.12 0.15 0.22 0.26 0.29 0.41 0.48 0.26 0.10 
ER 0.07 0.10 0.18 0.30 0.39 0.49 0.58 0.30 0.13 
O-Desalkyl-
quetiapine 
IR 0.014 0.015 0.022 0.028 0.036 0.040 0.042 0.028 0.010 
ER 0.005 0.016 0.029 0.035 0.052 0.089 0.093 0.041 0.021 
7-Hydroxy-
quetiapine 
IR 0.004 0.004 0.006 0.009 0.014 0.042 0.052 0.015 0.015 






IR 0.31 0.69 1.22 1.37 1.71 1.93 2.04 1.39 0.48 
ER 0.08 0.17 0.37 0.73 1.42 4.48 4.88 1.12 1.21 
O-Desalkyl-
quetiapine 
IR 0.054 0.071 0.115 0.133 0.170 0.213 0.218 0.142 0.052 
ER 0.018 0.039 0.065 0.095 0.132 0.232 0.382 0.109 0.069 
7-Hydroxy-
quetiapine 
IR 0.015 0.017 0.033 0.063 0.068 0.213 0.257 0.079 0.077 
ER 0.008 0.012 0.032 0.043 0.064 0.179 0.226 0.061 0.051 
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2.3.2.1 Regression analysis 
To assess the influence of independent variables including age, sex, quetiapine dose, time 
since last dose and formulation, regression analyses were undertaken using the plasma 
quetiapine and metabolite concentrations as dependent variables (Table 2.12). 
Plasma quetiapine concentration was not significantly influenced by any of the independent 
variables studied. Model strength was highest for O-desalkylquetiapine, where for an increase 
in plasma quetiapine concentration of 100 µg/L, O-desalkylquetiapine is predicted to increase 
by 4 µg/L. Quetiapine concentration was also a significant predictor of plasma 
7-hydroxyquetiapine, predicting a 3 µg/L increase in 7-hydroxyquetiapine concentration for 
every 100 µg/L increase in quetiapine concentration, although the model strength was lower in 
this instance. Dose was the most significant predictor of plasma N-desalkylquetiapine 
concentration, where an increase in 100 mg/d quetiapine dose predicted an increase in 
N-desalkylquetiapine concentration of 17 µg/L. The other variables in each model predicted less 
than 30 % of the overall model strength. 
 










B 95 % CI Beta P value 
Quetiapine 
concentration (µg/L) 








Quetiapine dose  
(100 mg/d) 
17.2 12.3, 22.0 0.45 <0.001 
Quetiapine concentration 
(µg/L) 
0.12 0.06, 0.17 0.25 <0.001 
(constant) 36.1 3.0, 69.2 - 0.03 













Quetiapine dose  
(100 mg/d) 
1.38 0.96, 1.81 0.29 <0.001 
(constant) 1.05 -1.9, 4.0 - 0.48 












(constant) 7.8 3.9, 11.7 - <0.001 
Excluded dose (p=0.62), sex (p=0.65), formulation (p=0.28), TSLD (p=0.20) 
* model and predictors explained in section 2.2.2.1 
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Regression analysis was also undertaken for the analyte C/D and MR (Table 2.13). Quetiapine 
C/D was not significantly influenced by any of the independent variables studied, and 
N-desalkylquetiapine C/D had a very low model strength. Both O-desalkylquetiapine and 
7-hydroxyquetiapine C/D were significantly predicted by quetiapine plasma concentration; an 
increase in quetiapine concentration of 700 µg/L predicted O-desalkylquetiapine C/D to increase 
by 0.1, and an increase in quetiapine concentration of 500 µg/L predicted 7-hydroxyquetiapine 
C/D to increase by 0.05. The MR could not be modelled for any metabolite.  
 
 
Table 2.13: Quetiapine audit: Regression data for dose-corrected quetiapine metabolite concentrations 





























































































 Excluded formulation (p=0.82), sex (p=0.74), age (p=0.55), TSLD (p=0.06), dose 
(p=0.03) 
* model and predictors explained in section 2.2.2.1 
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2.3.3 Co-prescribed medications 
Based on the possible activity on relevant enzymes, or where an impact on plasma quetiapine 
concentrations has been reported, the list of prescribed medications was searched for: 
carbamazepine, phenytoin, levomepromazine, valproate, clozapine, fluvoxamine, fluoxetine, 
citalopram, lamotrigine and oxazepam.  
There were no instances where phenytoin, levomepromazine, fluvoxamine, or oxazepam were 
mentioned. 
There were 70 patients that listed at least one medication other than quetiapine; therefore, the 
results from these 70 patients were used for investigation of the impact of co-prescribed 
medications. Comparison of groups prescribed and not prescribed relevant medications showed 
that overall there was very little impact of the co-prescribed medications (Table 2.14), possibly 
due to the small sample numbers available to study.  
Those results from patients prescribed lamotrigine had significantly higher N-desalkylquetiapine 
and O-desalkylquetiapine C/D than those not prescribed lamotrigine, and the results from 
patients prescribed fluoxetine had significantly higher N-desalkylquetiapine C/D and plasma 
N-desalkylquetiapine concentration than those patients not prescribed fluoxetine (Figure 2-3). 
 
 
Table 2.14: Quetiapine audit: Impact of co-prescribed medications 
Significant differences according to Mann Whitney U tests are listed. 
 
Co-prescribed medication N Significance between prescribed and non-prescribed groups * 
Lamotrigine 19 
O-Desalkylquetiapine C/D (p = 0.045) 
N-Desalkylquetiapine C/D (p = 0.049) 
Valproate 15 None 
Citalopram 6 None 
Fluoxetine 3 
N-Desalkylquetiapine C/D (p = 0.032) 
N-Desalkylquetiapine C (p = 0.038) 
Carbamazepine 3 None 
Clozapine 2 None 
* C = analyte concentration (µg/L), C/D = analyte concentration corrected for dose (µg/L per mg/d). 
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Figure 2-3: Quetiapine audit: Significant co-prescribed medication interactions 
Box = median and inter-quartile range, whiskers = range; Mann Whitney U p-value given between results 
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2.4 Discussion 
2.4.1 Plasma analyte concentrations and dose 
The strongest correlation found was between plasma quetiapine and O-desalkylquetiapine, 
which is in agreement with previous work (Fisher et al., 2012A), and between 
O-desalkylquetiapine and 7-hydroxyquetipiapine. This may suggest a close metabolic pathway 
between these analytes, or be related to the fact these metabolites are believed to be 
metabolised by minor enzymes rather than the major route through CYP 3A4. 
The table listing the plasma concentrations of quetiapine and its metabolites (Table 2.5) shows 
that for an increasing prescribed dose the median concentrations increased in line with dose, 
but there was much variation. These data will be helpful in assessing adherence, for example, 
in future quetiapine TDM samples. 
Correcting the plasma analyte concentrations for dose reduced the sample to sample variability 




 percentiles) for quetiapine down to a 30-fold 
variability, similar to the results found in other work (Bakken et al., 2011; Hasselstrøm and 
Linnet, 2004). As with this other work, the variability in quetiapine C/D was higher than that for 
N-desalkylquetiapine C/D, a finding thought to be related to the shorter half-life of quetiapine 
(Bakken et al., 2011), which would fit with our further findings that the variability for 
O-desalkylquetiapine and 7-hydroxyquetiapine C/D was between that for quetiapine and 






Regression analysis showed that the variability in O-desalkylquetiapine and 
7-hydroxyquetiapine plasma concentrations could be predicted most strongly by plasma 
quetiapine concentration. An increase in quetiapine dose predicted an increase in 
N-desalkylquetiapine plasma concentration, although the model strength was lower in these 
instances. The relationship between the plasma analyte concentrations and dose was 
significant, but poor, with the best relationship between quetiapine and N-desalkylquetiapine 
(0.56). These results compare well with those calculated in the previous audit (Fisher et al., 
2012A), and agree with the findings of Bakken et al. (2011). 
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The variability in quetiapine and N-desalkylquetiapine C/D was not significantly influenced by 
any of the independent variables, although O-desalkylquetiapine and 7-hydroxyquetiapine C/D 
were predicted to increase with an increase in plasma quetiapine concentration. 
2.4.2 Metabolic ratio 
Median MR showed overall that N-desalkylquetiapine reached equivalent plasma 
concentrations to quetiapine, while O-desalkylquetiapine was ten-times lower and 
7-hydroxyquetiapine twenty-times lower than plasma quetiapine concentrations. MR could not 
be modelled for any metabolite, although a correlation was found where MR increased with 
increasing dose, matching the finding of Bakken et al. (2011). 
2.4.3 Age and sex 
Increasing age correlated to a decrease in prescribed quetiapine dose, MR of 
N-desalkylquetiapine and 7-hydroxyquetiapine, and in 7-hydroxyquetiapine concentration, but 
an increase in quetiapine C/D. This agrees with the results from other studies where quetiapine 
C/D was higher in patients aged over 65 or 70 (Bakken et al., 2011; Castberg et al., 2007; 
Hasselstrøm and Linnet, 2004; Wittmann et al., 2010). Higher plasma quetiapine concentrations 
were attained at the same dose as age increased, suggesting a reduced metabolic capacity 
possibly related to reduced hepatic blood flow; this suggestion is supported by a decreasing MR 
for both N-desalkylquetiapine and 7-hydroxyquetiapine with increasing age.  
Neither age or sex were significant predictors of the variation in plasma analyte concentrations, 
analyte C/D or analyte MR.  
There was no difference between males and females for prescribed quetiapine dose, plasma 
quetiapine concentration or quetiapine C/D, however there was a significant difference in C/D 
for both N-desalkylquetiapine and O-desalkylquetiapine. One group suggested quetiapine C/D 
was higher in females, though not when weight corrected (Hasselstrøm and Linnet, 2004). 
However, the results presented here agree with other work where no differences were found 
between males and females (Bakken et al., 2011; Handley et al., 2013) 
2.4.4 Formulation 
Formulation was recorded for 49 patients. Quetiapine plasma concentration, quetiapine C/D and 
O-desalkylquetiapine C/D were significantly higher in patients prescribed ER formulation that IR 
formulation, and N-desalkylquetiapine MR was significantly lower (Table 2.11). The rate of 
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liberation of quetiapine from the ER formulation is the reason why the quetiapine plasma 
concentration and C/D is affected by formulation. O-Desalkylquetiapine and 
7-hydroxyquetiapine plasma concentrations and C/D were also higher in the ER formulation 
group, although this difference was not always significant. N-Desalkylquetiapine was much less 
affected by formulation, with very little difference between both plasma concentration and C/D. 
Therefore, it followed that the MR was affected due to the impact on quetiapine, likely due to the 
short plasma half-life of quetiapine, not being matched by a similar impact on 
N-desalkylquetiapine with its longer plasma half-life (7 and 11 hours, respectively). 
2.4.5 Time since last dose 
Time since last dose was recorded in 150 cases, with 118 samples taken between 10 to 
15 hours, and 32 samples taken over 15 hours post-dose. Between the two groups (10 to 
15 hours post-dose and over 15 hours post-dose) there was only significant difference in the 
quetiapine and O-desalkylquetiapine plasma concentrations, which is in line with the short 
plasma half-life of quetiapine and close relationship between quetiapine and 
O-desalkylquetiapine. These results match those where quetiapine C/D in samples taken 
10 hours post-dose were higher than those taken 14 hours post-dose, and they found no 
difference in N-desalkylquetiapine C/D (Bakken et al., 2011).  
2.4.6 Co-prescribed medications 
Metabolism of quetiapine occurs primarily by CYP 3A4, with CYP 3A5 and CYP 2D6 playing a 
minor role (Figure 2-1). It would therefore be expected that polymorphisms of these enzymes 
and relevant transporters such as PGP could affect quetiapine exposure, hence the presence of 
co-prescribed medications which impact the activity of relevant enzymes are also likely to 
impact quetiapine exposure. 
Agreement on the impact of polymorphisms on quetiapine exposure is not conclusive; 
polymorphisms in CYP 3A4 have been reported to affect quetiapine exposure (van der Weide 
and van der Weide, 2014), affect N-desalkylquetiapine but not quetiapine exposure (Bakken et 
al., 2015), or have no impact on either quetiapine or N-desalkylquetiapine exposure (Nikisch et 
al., 2010), although sample numbers were small in this latter study. CYP 2D6 polymorphisms 
were said to have no impact on either quetiapine or N-desalkylquetiapine concentrations in a 
small study (Nikisch et al., 2010), and an impact only on N-desalkylquetiapine exposure in a 
 Page 48 
larger study (Bakken et al., 2015). Polymorphisms of CYP 3A5 may affect quetiapine 
pharmacokinetics (Kim et al., 2014), possibly through the formation of other minor metabolites, 
such as O-desalkylquetiapine (Bakken et al., 2009), although an effect was not seen on either 
quetiapine or N-desalkylquetiapine exposure in another study (Bakken et al., 2015). Quetiapine 
is also believed to be transported across cell membranes and also across the blood-brain 
barrier by PGP, but the presence of a polymorphism in the encoding gene (ABCB1) was not 
found to have significant effects on plasma quetiapine concentrations in some studies (Bakken 
et al., 2015; Kim et al., 2014), although another report suggests ABCB1 genetic polymorphisms 
play a large part in quetiapine exposure (Nikisch et al., 2010).  
With regards to non-genetic effects on CYP activity, the results are again inconclusive, possibly 
due to small sample numbers in the studies. Lower quetiapine concentrations have been 
observed in patients co-prescribed CYP 3A4 inducers such as carbamazepine and phenytoin, 
either as a reduction in quetiapine C/D (Bakken et al., 2011; Castberg et al., 2007; Hasselstrøm 
and Linnet, 2004) or an increase in quetiapine clearance (Isbister et al., 2007; Wittmann et al., 
2010; Wong et al, 2001). N-Desalkylquetiapine C/D was also found to be slightly lower in 
patients prescribed CYP 3A4 inducers (Bakken et al., 2011). Co-ingestion of CYP 3A4 inhibitors 
decreased quetiapine clearance (Isbister et al., 2007), and co-prescription of valproate, 
recorded as an inhibitor of both CYP 3A4 and CYP 2D6, significantly increased quetiapine 
concentrations (Aicchorn et al., 2006). Drugs that interact with CYP 2D6, including 
levomepromazine, did not display higher quetiapine C/D than the remainder of the group 
(Hasselstrøm and Linnet, 2004). Other medications investigated showed that co-prescription of 
clozapine, fluvoxamine and citalopram were associated with increased quetiapine C/D, whereas 
lamotrigine and oxazepam decreased quetiapine C/D (Castberg et al., 2007). 
In this work, there were only a limited number of cases which referred to co-prescribed 
medications, and therefore this limited statistical significance. Only 2 medications impacted any 
of the results: patients prescribed lamotrigine had significantly higher N-desalkylquetiapine and 
O-desalkylquetiapine C/D than the group not prescribed lamotrigine, and the patients prescribed 
fluoxetine had significantly higher N-desalkylquetiapine C/D and plasma N-desalkylquetiapine 
concentration. Multiple concurrent medications and possible dose-related influence, neither of 
which could be studied, add to the complexity of predicting the influence of co-prescribed 
medication in an individual.  
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An impact of lamotrigine in decreasing quetiapine C/D has been reported, although a 
mechanism for such an effect was not discussed (Castberg et al., 2007). It is possible that 
lamotrigine interaction was through PGP inhibition (Weiss et al., 2003) or tissue-specific 
CYP 3A4 inhibition (Perucca, 2005). Whatever the route, it seems that clearance of 
N-desalkylquetiapine and O-desalkylquetiapine is inhibited by lamotrigine without having a 
significant impact on either quetiapine or 7-hydroxyquetiapine clearance, possibly related to this 
metabolite being metabolised primarily by CYP 2D6.  
In the present study, fluoxetine was found to increase the N-desalkylquetiapine C and C/D, but 
had no impact on the plasma quetiapine concentrations or other metabolites studied. Fluoxetine 
is a CYP 2D6 inhibitor, although norfluoxetine may be a 3A4 inhibitor (Hemeryck and Belpaire, 
2002). It is believed that N-desalkylquetiapine is formed through CYP 3A4 activity (Figure 2-1), 
therefore norfluoxetine may have a larger impact than previously shown, or inhibition of 
CYP 2D6 may inhibit the minor metabolic route leading to an increased proportion of the dose 
giving rise to N-desalkylquetiapine.  
2.4.7 Application of the metabolites in quetiapine TDM 
Previous work has shown that there is no clear evidence of a target range for plasma quetiapine 
with respect to clinical response (Sparshatt et al., 2011).  
This work has shown that analysis of the quetiapine metabolites can provide further information 
in plasma quetiapine TDM. Measurement of N-desalkylquetiapine has been shown to be helpful 
in assessing quetiapine exposure, at least in part due to the reduced variability between 
samples due to its longer plasma half-life. The other two metabolites investigated here have a 
similar though slightly longer plasma half-life to quetiapine, and O-desalkylquetiapine shows a 
very close relationship to quetiapine. Age plays a significant role in either the formation, or 
clearance of 7-hydroxyquetiapine, possibly more so than quetiapine or the other metabolites. 
Plasma concentrations of the quetiapine metabolites cannot be predicted by age, sex, dose or 
time since last dose. 
This work has established dose-related plasma concentration ranges for quetiapine and the 
metabolites studied, and highlighted the different expected concentrations attained in samples 
from patients prescribed IR and ER quetiapine. The variability in plasma quetiapine 
concentrations as established by the dose-related concentration data supports the use of 
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metabolites to assess quetiapine exposure, since the metabolite plasma concentrations were 
found to increase with increasing dose, a finding not matched by study of quetiapine itself. 
It should be noted that one limitation of the audit undertaken is that these samples are routine 
TDM samples, therefore the reason that these analyses were requested is not known. There 
may be cases where the patient has become stabilised on a dose at which they are responding 
to, and TDM is undertaken to establish the steady state stable concentrations for future 
comparisons; However, there may also be cases where the patient is not responding to the 
medication and adherence is being assessed. As such, the concentrations reported may not 
correlate to a reference range for clinical response. 
One possible way to achieve a greater benefit from application of the quetiapine metabolites is 
to undertake an audit of only those results obtained from patients known to be responding 
clinically to the medication. This investigation could be extended to subdivide response to the 
different diagnoses such as successful treatment of schizophrenia, depression, anxiety and 
sleep disorder. To obtain a dataset of samples only from those patients who are responding to 
the treatment would require a clinical trial to be undertaken across a large number of units; 
however the benefits to this effort could enable therapeutic reference ranges of quetiapine and 
its plasma metabolites to be established in order to guide quetiapine therapy in the future and 
improve treatment success in these patients. 
The aims of this work have been achieved, a dataset was created and the results analysed. 
Whilst studied alone the metabolites may not provide conclusive evidence of quetiapine 
exposure, but they can provide further information to help interpret plasma quetiapine TDM 
results. Overall, the evidence suggests an ongoing benefit to quantifying these additional 
metabolites, and further work looking at the concentrations in line with clinical response, both for 
schizophrenia and in depressive disorders, could enable reference ranges for quetiapine and 
the metabolites studied to be established. Dose-related plasma quetiapine metabolite 
concentrations have been presented herein and can be used to interpret future plasma 
quetiapine metabolite results. 
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Chapter 3.  Potential role of oral fluid in antipsychotic TDM: 
method development and assessment 
3.1 Introduction 
The technique of oral fluid collection can vary from the drool method (unstimulated pooling of 
oral fluid in the mouth and spitting into a tube), collection into a buffered liquid held in the mouth, 
or collection using an adsorbent pad held in the mouth that is either untreated, or treated for 
example with an acidic buffer to further stimulate oral fluid flow. With each collection technique, 
there are different analytical considerations, including the pH of the fluid collected, analyte 
recovery from a pad, and compensation for any dilution effect during sample collection.  
The two collection devices used in this study were the GBO and Oral-Eze collection systems 
(Figure 3-1). Both devices use a stimulated collection, for the GBO device a buffered solution is 
held in the mouth and subsequently collected for analysis and for the Oral-Eze device an 
adsorbant pad is held in the mouth and then stored post-collection within a buffered solution. 
These differing collection techniques will allow comparison of the in-mouth buffering device 
against one that collects only moderately stimulated oral fluid in uncontrolled oral cavity pH. 
Therefore the theoretical improvement proposed from the buffering to reduce between patient 
and between collection oral fluid pH can be directly assessed. 
 
3.1.1 GBO oral fluid collection device 
The GBO device consists of four components: (1) a mouth wash that is used immediately prior 
to OF collection, (2) 4 mL of collection buffer containing a food dye (tartrazine) that is held in the 
mouth for 2 minutes, (3) a beaker into which the buffer solution is spat, and (4) two tubes 
containing the preservative sodium azide that are used to securely collect the sample from the 
beaker to be sent for analysis (Greiner Bio One, 2011; Figure 3-1). Tartrazine contained within 
the collection buffer is used to quantify the amount of oral fluid contained within the final 
collection fluid by calculation of the dilution of the original tartrazine concentration, and sodium 
citrate is used to buffer the solution during collection (approx. pH 4-6) and to stimulate oral fluid 
flow. 
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Figure 3-1: Oral fluid collection devices images. 
(a) GBO collection device: i) collection buffer, collection beaker and saliva transfer tubes, ii) once the 
collection buffer has been held in the mouth for 2 minutes, the solution is spat into the beaker, and the 
saliva transfer tube is inserted into the lid to take up the sample securely, iii) the sealed saliva transfer tube 
can then be stored or analysed directly. 
(b) Oral-Eze collection device: i) the collection device is attached to a handle and received with a collection 
buffer tube, ii) the pad is held against the cheek until the indicator window turns blue or at 10 minutes and 
then the pad is dispensed off the handle into the collection buffer, iii) the pad is plunged down to enable 
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Accurate measurement of tartrazine within the collected fluid is a vital part of accurate analyte 
quantification, whether within a single method together with the drugs under study or separately, 
since the degree of dilution of the oral fluid collection solution varies from sample to sample. 
3.1.2 Oral-Eze oral fluid collection device 
The Oral-Eze device consists of an adsorbant collection pad of untreated pure cotton fibre that 
is held in the mouth until the indicator on the handle turns blue to indicate that 1 mL oral fluid 
has been collected (or for a maximum of 10 minutes). The pad is then detached into a tube 
which contains 2 mL of a buffer (approx. pH 4-6) for storage until analysis (Thermo Fisher 
Scientific, 2013; Figure 3-1).  
Quantification of the analytes from this sample must take into account the 1+2 dilution of oral 
fluid into the buffer post-collection. This device works on the assumption that a fixed volume of 
oral fluid is collected, and therefore no further compensation for sample volume is required, 
although possible loss of analyte via adsorption onto the pad must be taken into account. 
3.1.3 Analytical considerations 
Oral fluid samples collected using both collection devices are stored under acidic conditions in a 
buffer at approximately pH 4-6; hence this must be taken into account during sample 
preparation if pH dependent extraction is undertaken.  
Assessment of whether a method is fit-for-purpose is a critical part of implementing a new 
method, as it is necessary to show that a method is accurate and precise, as well as sensitive 
enough to detect the analytes in question and selective enough that interferences are known or 
minimised where possible; in essence ensuring that the results reflect the concentration of the 
analyte in the relevant matrix at the time of sample collection, and that results are reproducible 
and reliable. For liquid chromatographic-mass spectrometric (LC-MS) assays it is important to 
ensure that the effects of ion suppression/enhancement sample to sample are assessed and 
minimised (Matuszewski et al., 2003). 
The value of quetiapine metabolite assay in quetiapine has been discussed in Chapter 2, 
therefore these were included in the analytes studied. 
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3.1.4 Aims of the chapter 
The established methodology for the measurement of atypical antipsychotics in plasma (Fisher 
et al., 2013B; Fisher et al., 2012B) will be combined and extended to include clozapine and 
norclozapine, and fluoxetine and norfluoxetine, to detect all analytes within a single analytical 
procedure. 
Methods for the analysis of tartrazine in the GBO collected fluid will be investigated, first in a 
combined method with the analytes of interest so that only a single step is required for the 
patient sample analysis, and if this is unsuccessful methods for a separate method will be 
investigated.  
The sample preparation procedure will be modified in order to facilitate use with oral fluid, taking 
into account the larger sample volume available as compared to plasma and the acidic nature of 
the buffered collection fluid. Separate methods will be created if necessary for the extraction 
from each oral fluid collection device to account for the different collection processes. 
Both oral fluid methods will be assessed to ensure they are fit-for purpose. 
3.2 Materials and instrumentation 
3.2.1 Materials 
Aripiprazole and dehydroaripiprazole were from Bristol-Myers Squibb (New York, USA). 
Bis-quetiapine fumarate was from AstraZeneca (London, UK). Clozapine and norclozapine were 
from Novartis (Frimley, UK). Olanzapine was from Eli Lilly (Indianapolis, USA). Risperidone and 
(±)-9-hydroxyrisperidone were from Janssen (Beerse, Belgium). Quetiapine-D8 fumarate, 
(±)-amisulpride-D5, dehydroaripiprazole-D8, fluoxetine, norfluoxetine, fluoxetine-D6, quetiapine, 
N-desalkylquetiapine, N-desalkylquetiapine-D8, O-desalkylquetiapine, 7-hydroxyquetpiapine, 
7-hydroxyquetpiapine-D8, norfluoxetine-D5, risperidone-D4, (±)-9-hydroxy-risperidone-D4 and 
(±)-sulpiride-D3 and were from LGC Standards (Teddington, UK). Aripiprazole-D8 was from 
Medical Isotopes (Pelham, USA). Clozapine-D8, norclozapine-D8, and olanzapine-D3 were from 
Toronto Research Chemicals (Ontario, Canada). Butyl acetate, butanol and methanol (all HPLC 
grade) were from Rathburn (Walkerburn, Scotland). Ammonium acetate, tris(hydroxymethyl)-
aminomethane (Tris; Trizma, >99.5 %), (±)-amisulpride, (±)-sulpiride, tartrazine, and newborn 
calf serum were from Sigma-Aldrich (Poole, UK). Acetic acid (Fluka ACS reagent), ammonia 
(28 %) and hydrochloric acid (both BDH AnalaR grade) and low-volume (max 1 mL) cuvettes 
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were from VWR (Lutterworth, UK). Pooled human dipotassium EDTA plasma was from Sera 
Laboratories International (West Sussex, UK). GBO collection systems, quantification kits and 
the blank buffer solution were donated by Greiner Bio-One (Stonehouse, UK). Oral-Eze 
collection system kits and blank buffer solution were donated by Thermo (Loughborough, UK). 
Blank oral fluid was collected according to the protocol for each collection system from drug-free 
volunteers and stored at -18 to-20 ºC until required. Polypropylene 2 mL tubes were from 
Alphalabs (Eastleigh, UK). Eppendorf flip-cap centrifuge tubes 1.5 mL were from Elkay 
(Basingstoke, UK). Autosampler vials 0.5 mL were from Sarstedt (Leicester, UK). Dreyer tubes, 
60.5 x 7.5 mm i.d. glass test tube, were from Esslab (Essex, UK). 0.45 µm nylon Phenex filters 
were from Phenomenex (Macclesfield, UK). The pH probe was a LIQ-GLASS BNC combination 
electrode (Hamilton; Bonaduz, Switzerland) calibrated against aqueous buffers (pH 4, 7 and 10, 
Merck, Darmstadt, Germany). Water was deionised (Purite Select) to resistivity greater than 
12 MΩ/cm. 
The LC eluent was ammonium acetate (50 mmol/L) in methanol, filtered, and adjusted to 
apparent pH 6.0 with acetic acid. 
The pH of the oral fluid collection device solutions and samples were tested using pH strips 
(Fisherbrand pH indicator paper sticks range 0-14, Fisher Scientific). 
3.2.2 Instrumentation 
The LC pump (PU-1580), column oven (CO-2067) and autosampler (AS-950) were from Jasco 
(Great Dunmow, UK). The guard cartridge and analytical column (stainless steel, 10 and 100 x 
2.1 mm i.d., respectively) were packed with Waters Spherisorb S5SCX 5 µm sulfopropyl-
modified silica (Hichrom, Reading, UK). The eluent flow-rate was 0.5 mL/min. Analytes were 
measured using selected reaction monitoring (SRM; sum of two product ions) following positive 
mode atmospheric pressure chemical ionisation (APCI; TSQ Quantum Access, ThermoFisher 
Scientific, Hemel Hempstead, UK). Quantification was by the sum of the peak area of both 
transitions as a ratio to the sum of the peak area of both transitions of the corresponding 
internal standard. Other ionisation source settings were: corona discharge current 4 µA; 
vaporiser and capillary temperatures 320 and 300 °C, respectively; auxiliary, sheath and ion 
sweep gas settings 5, 40, and 0 arbitrary units, respectively (Fisher et al., 2013B). High purity 
argon was used as collision gas (1.5 mTorr). Data acquisition and processing were via Xcalibur 
(version 2.0.7, ThermoFisher Scientific). 
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The spectrophotometer used for tartrazine assay was from Jenway (model 6315; Stone, UK) 
and data were recorded directly from the on-screen readout of the extinction at 450 and 
520 nm.  
 
3.3 Method development for tartrazine quantification in the GBO 
system  
Successful use of the GBO system relies on the accurate quantification of tartrazine within the 
collection fluid. Tartrazine is a polar, hydrophilic dye, therefore analysis was not possible using 
LLE with SCX chromatography. Thus, different chromatographic techniques were investigated. 
 
3.3.1 Analysis of tartrazine by MS detection 
Reversed phase (RP) chromatography was investigated using a methanol-water gradient and 
an ACE C18 column (100 x 2.1 mm, 3 µm packing, flow rate 0.5 mL/min). 
Sunset yellow was investigated simultaneously as an IS for tartrazine quantification since it is a 
similar compound in chromophore and size (molar mass 452.37 g/mol). Mass spectrometric 
conditions established for the quantification of tartrazine and sunset yellow were investigated. 
The tartrazine precursor ion would be expected to be based on the molar mass (534.36 g/mol) 
however since tartrazine has sodium present the precursor ion was found to be different in two 
papers both using electro-spray ionisation (ESI) with detection by either MS or MS/MS (Ma et 
al., 2006; Ates et al., 2011). Ma et al., 2006, used single quadrupole MS in negative ionisation 
mode at mass ions for tartrazine of 467 [M-3Na+2H]
-
 and 423 [M-3Na+2H-CO2]
-
, and for sunset 
yellow 407 [M-2Na+H]
-
 and 429 [M-Na]
-
. Ates et al., 2011, used an MS/MS method using 
precursor ions 470.87 in positive ionisation mode monitoring no products for tartrazine, and 
407.01 to product ions 206.55 and 142.35 for sunset yellow in negative ionisation mode.  
Given the disparity in these papers between positive and negative ionisations for tartrazine, 
both of these ionisation polarities were investigated. Infusing directly into the instrument using 
ESI and APCI, in both positive and negative polarities gave no distinct predominant m/z peaks 
for either analyte at the ranges investigated, suggesting this analysis was not viable under the 
conditions studied. 
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3.3.2 Analysis of tartrazine by LC with UV detection 
In-line UV is a useful way to detect analytes simultaneously within a single sample when the 
analytes display different physiochemical properties. The UV detector available used a 
deuterium lamp with maximum emitted wavelength of 370 nm. Both tartrazine and sunset yellow 
have maximum absorbance within the visible light range (tartrazine around 427 nm, sunset 
yellow in the region of 480-500 nm), therefore a non-maximal peak wavelength of 258 nm had 
to be selected to utilise the available UV lamp. 
A test solution was prepared containing all analytes (antipsychotics as well as tartrazine and 
sunset yellow, 1 mg/L) and injected using a scouting gradient of 5 % to 100 % methanol-based 
eluent and full scan MS for the antipsychotics and UV for the dyes tested at both 370 nm and 
258 nm. All other relevant analytes were retained and separated, and a 15-70 % methanol 
gradient enabled all analytes to elute in 9 minutes with a 5.8 minute re-equilibration step (Figure 
3-2).  
No response was detected for tartrazine either by UV (both wavelengths) or MS, suggesting 
that tartrazine may have eluted in the solvent front. Reversing the gradient direction gave the 
same results suggesting that tartrazine does not interact with the C18 column.  
Simple spectrophotometry was therefore considered for tartrazine analysis.  
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Figure 3-2: Development of a reversed phase chromatographic method for analytes of interest. 
MS conditions using full scan in Q3, 0.5 sec scan time, m/z 100-600 and extracted relevant ions. Mobile 
phase A = 99 % water, 1 % methanol with 0.1 % (v/v) formic acid; B = methanol with 0.1 % (v/v) formic 
acid. 
(a) Gradient 5 % to 100 % B (21 min) to 5 % B (21.2 min) and equilibrate up to 28 min  
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3.3.3 Tartrazine by spectrophotometry 
The commercial quantification method recommended measurement of the extinction 
coefficients for two wavelengths and calculation of the extinction difference (450 nm minus 
520 nm; Greiner Bio-One, 2011). The wavelength response at 520 nm was used to establish 
the degree of cloudiness of the sample where proteins (e.g. mucin) and particulate matter 
non-specifically interfere, thereby leaving the specific wavelength result for 450 nm. The kit 
contained 5 calibrator solutions, 2 quality control solutions. 
As a modification of the recommended analyser approach that could not be used due to the 
absence of a suitable automated analyser, a manual spectrophotometric method was designed 
where the samples were analysed in series by the first wavelength, recording the extinctions, 
and then changed to the second, and the results again recorded. An Excel spreadsheet was 
created containing a template of the calibrator values, the extinction difference calculated, and 
the results plotted to form a calibration curve (calculating the gradient, intercept and correlation) 
from which to calculate the results of samples analysed in U/mL (units of oral fluid per mL of 
collection fluid) as per the kit. Results were converted to give the percentage of oral fluid 
contained within the collection fluid (% oral fluid) by the result in U/mL multiplied by 100. This 
value could then be used to correct the analyte concentration within the collection fluid.  
Although SGAs do not generally have an absorbance within the visible wavelength, potential 
interferences had to be ruled out. Blank oral fluid was collected as per the collection protocol 
from a drug-free volunteer and a portion set aside to verify the oral fluid content prior to addition 
of the analytes. A solution was made at 100 µg/L (all antipsychotics) using part of the volunteer 
sample, and analysed alongside the blank. Results were compared and there was no difference 
found in the calculated oral fluid content between the blank solutions and those with the added 
analytes, suggesting that as expected the presence of antipsychotics did not interfere with 
tartrazine quantification.  
Blank buffer solution was provided by GBO that was equivalent to the extraction solution to be 
held in the mouth, but containing the preservative sodium azide, normally added at the final 
stage post-collection. In order to confirm this displayed the same spectrophotometric response 
as the solution prior to collection and the collection fluid following the complete protocol with 
sodium azide added, a comparison was undertaken. Oral fluid was collected from a volunteer, 
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however when spat into the beaker a portion was separated out so that it didn’t contain sodium 
azide, and the remainder taken up as normal into the transfer tube containing sodium azide. A 
comparison between the directly analysed blank buffer solution and the volunteer samples with- 
and without-azide showed equivalent response of oral fluid content irrespective of the azide 
presence. The blank buffer solution was calculated to contain zero oral fluid content as 
expected (following dilution with deionised water to bring the tartrazine within the calibration 
range). All samples also all displayed the same pH (4-6) as measured by pH strips. The buffer 
solution could therefore be used as a blank for the creation of the calibration solutions if 
deemed appropriate by the recovery studies.  
 
3.4 Method development for the antipsychotics 
As tartrazine was not assayable by LC, development of the antipsychotic assay was undertaken 
using LLE-SCX. 
 
3.4.1 Mass spectrometric conditions 
Analyte transitions and MS conditions were taken from Fisher et al. (2013B) and Fisher et al. 
(2012B). Analyte tuning was undertaken for fluoxetine and norfluoxetine, and for the internal 
standards fluoxetine-D6 and norfluoxetine-D5. Product ions were selected based on the intensity 
of the response and the gases and temperature settings selected as per the other analytes 
within the published methods (Table 3.1).. Injection of test solutions containing each analyte 
(1 mg/L) showed no cross-talk and adequate sensitivity, therefore these transitions were added 
to the method (Table 3.1).  
Upon starting the method assessment, poor reliability was identified for the new analytes, 
especially norfluoxetine. These analytes fragmented only to one major product ion within the 
range usually selected (>100 m/z), therefore in order to achieve 2 product ions a smaller than 
ideal ion was monitored. Investigation showed non-specific variability in the lower m/z product 
(between 30 and 44 m/z) and investigation of other transitions showed similar poor robustness 
or poor abundance; therefore a single product ion was selected for each of these analytes (at 
slightly higher collision energy) for the subsequent analysis.  
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Table 3.1: Mass spectrometric detection and  analyte settings  
Detection was by positive ion APCI. MS/MS settings: corona discharge current 4 µA; vaporiser and 
capillary temperatures 320 ºC and 300 °C respectively; auxiliary, sheath and ion sweep gas settings 5, 35, 















N-Desalkylquetiapine 296.03 103 139.1 52 210.0 28 
Norfluoxetine 
296.06 84 30.6 20 134.1 5 
* 296.06 84 134.1 10 - - 
Norfluoxetine-D5 
301.10 83 32.5 38 139.2 5 
* 301.13 83 139.2 10 - - 
N-Desalkylquetiapine-D8 303.99 105 182.9 37 209.8 28 
Fluoxetine 
310.07 85 44.5 12 148.1 5 
* 310.07 85 148.1 10 - - 
Norclozapine 313.04 90 192.1 38 270.0 21 
Olanzapine 313.12 83 198.0 36 256.1 20 
Olanzapine-D3 316.04 87 198.0 40 256.0 21 
Fluoxetine-D6 
316.10 84 44.2 12 154.2 6 
* 316.13 84 154.2 10 - - 
Norclozapine-D8 321.20 93 192.1 39 275.1 23 
Clozapine 327.09 86 192.1 40 270.1 20 
Clozapine-D8 335.14 90 192.0 43 275.0 23 
O-Desalkylquetiapine 340.05 101 210.0 33 253.0 20 
Sulpiride 342.10 86 112.2 24 214.0 30 
Sulpiride-D3 345.00 107 112.1 26 216.8 31 
Amisulpride 370.11 84 195.6 39 242.0 25 
Amisulpride-D5 375.14 85 196.0 38 242.0 26 
Quetiapine 384.07 100 221.1 34 253.0 21 
Quetiapine-D8 392.13 110 226.1 36 258.0 22 
7-Hydroxyquetiapine 400.06 113 208.0 39 237.0 36 
7-Hydroxyquetiapine-D8 408.09 95 241.0 34 274.0 23 
Risperidone 411.15 86 110.1 42 191.1 26 
Risperidone-D4 415.17 84 114.2 44 195.1 29 
9-Hydroxyrisperidone 427.14 95 110.1 37 207.1 26 
9-Hydroxyrisperidone-D4 431.09 118 114.0 38 211.0 25 
Dehydroaripiprazole 446.08 93 98.0 34 285.0 22 
Aripiprazole 448.10 105 176.0 30 285.0 23 
Dehydroaripiprazole-D8 454.15 97 106.3 35 293.1 23 
Aripiprazole-D8 456.15 100 176.1 30 293.1 25 
* Final settings indicated for fluoxetine, norfluoxetine and ISs. 
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3.4.2 Method development: plasma 
All analytes of interest were not currently analysed within a single detection method (Fisher et 
al., 2013B; Fisher et al., 2012B), therefore the detection settings were combined as per section 
3.4.1. Existing plasma calibration and IQC solutions for the SGAs and quetiapine metabolites 
were analysed on the combined method using the transitions as per Table 3.1 and extracted 
according to the published reports (summarised in Figure 3-3) . All results matched according to 
the nominal values from the individual methods; therefore the combined method was accepted 
for plasma analysis. 
3.4.3 Optimising sample preparation for the GBO system 
Use of LLE to extract the analytes from the sample matrix enables sample preparation to be 
very selective when optimised correctly. The existing plasma LLE extraction (Figure 3-3) uses 
100 µL of 2 mol/L Tris solution at pH 10.6 to adjust the pH enabling optimum extraction of the 
analytes in question (two pH units above the pKa of most of the analytes). 
The GBO collection solution buffered the collected oral fluid sample to approximately pH 4-6 
with sodium citrate within the collection device. Therefore use of 2 mol/L Tris solution at pH 10.6 
to extract the analytes from this acidic buffer solution was unlikely to modify the pH of the 
collection fluid to the desired basic pH without adding a very large volume of buffer. As such, 
stronger bases (higher pH) were investigated so that a small volume of basic solution could be 
added yet still buffer the solution to approximately pH 10-11. Use of too high a pH was avoided 
due to the risk of degradation of the analytes and metabolites. 
Taking separate 1 mL portions of the buffer solution (initial pH 4-6), ammonium and sodium 
hydroxide (both 1 mol/L) were added to each portion and the pH tested. The results (Figure 3-3) 
showed that adding 50 µL ammonium hydroxide solution to 1 mL of buffer gave an appropriate 
extraction pH. 
To confirm that the presence of oral fluid did not affect the pH reached when using the 
ammonium hydroxide solution, the experiment was repeated using blank oral fluid collected 
from a volunteer. Analogous results were obtained; hence this sample preparation method was 
further evaluated. 
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Figure 3-3: Summary of the plasma LLE sample extraction process. 
 
Sample (200 µL; plasma) to glass Dreyer tube
Tris pH 10.6 (2 mol/L; 100 µL)
Vortex mix (5 s)
Butyl acetate:butanol (9+1; 100 µL)
Vortex mix (30 s)
Centrifuge (12,000 g; 4 min)
Transfer > 40 µL of extract to autosampler vial
Inject 20 µL




Table 3.2: Oral fluid sample pH adjustment testing results 
 
Basic solution (1 mol/L) Volume added to 1 mL buffer solution (µL) pH achieved 
Sodium hydroxide 25 pH 9-10 
Sodium hydroxide 50 pH 13 
Ammonium hydroxide 50 pH 10-11 




Figure 3-4: Summary of the oral fluid LLE sample extraction process. 
(a) Initial development; and (b) optimised method.  
Sample (1 mL) to 2 mL tube
Ammonium hydroxide 
(1 mol/L; 50 µL)
Vortex mix (5 s)
Butyl acetate:butanol (9+1; 100 µL)
Vortex mix (30 s)
Centrifuge (12,000 g; 4 min)
Transfer > 40 µL of extract to autosampler vial
Inject 20 µL
Sample (0.5 mL) to 1.5 mL tube
Internal standard (0.2 mg/L; 25 µL)
Vortex mix (5 s)
Butyl acetate:butanol (9+1; 125 µL)
Vortex mix (30 s)
Centrifuge (12,000 g; 4 min)
Transfer > 40 µL of extract to autosampler vial
Inject 20 µL
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To ensure adequate analyte sensitivity, a sensitivity test solution of all analytes (10 µg/L) in 
blank GBO buffer solution was extracted using 50 µL of ammonium hydroxide (Figure 3-4a). 
Sensitivity was adequate, although a degree of emulsification was observed in some extracts. 
Due to the inconvenience of using screw cap 2 mL tubes for sample extraction, an alternative 
1.5 mL flip-cap tube was investigated. A reduction in sample volume to 0.5 mL was therefore 
tested using 25 µL ammonium hydroxide solution and the volume of extraction solvent was 
increased to 125 µL to prevent emulsions from forming. The sensitivity test solution (10 µL, all 
analytes) was extracted again using the modified method (Figure 3-4b) using an internal 
standard solution (0.2 mg/L, all internal standards, in 0.1 mol/L hydrochloric acid). The results 
using the modified method showed good sensitivity and signal to noise ratio for all analytes and 
internal standards (Figure 3-5:a) and therefore this sample preparation method was adopted. 
 
3.4.4 Optimising sample preparation for the Oral-Eze system 
With sample preparation and extraction optimised for the GBO system, a similar protocol was 
followed to ensure the accurate assay of samples collected via the Oral-Eze system. 
The collection solution for the Oral-Eze system was similar to that of the GBO system in that it 
was an acidic solution, therefore it was thought that a similar LLE method would be possible. As 
such, repeating the pH tests showed that use of 25 µL ammonium hydroxide solution (1 mol/L) 
added to 0.5 mL Oral-Eze buffer successfully increased the pH of the collection solutions to pH 
10-11. Due to the dilution 1+2 of the oral fluid into collected buffer, the sensitivity experiments 










Figure 3-5: Results of the oral fluid sample extraction sensitivity tests.  
Extraction of a test solution (20 µg/L group A analytes, 5 µg/L group B analytes, 2 µg/L group C analytes; analyte groups as per Table 3.3) using 0.5 mL sample volume as per the 
protocol. 
(a) Test solution made in GBO buffer 
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3.5 Method assessment  
3.5.1 Method assessment protocol 
Calibration (N = 7) and internal quality control (IQC; N = 3) solutions were prepared separately in 
combined groups with the analytes at 3 different concentrations depending on the expected 
analyte concentrations predicted from plasma concentrations (Table 3.3). 
The antipsychotic methods were assessed based on the FDA guidelines for bioanalytical 
methods (FDA/CDER, 2001) including within- and between-batch accuracy and imprecision 
calculated from the IQC solutions, limit of detection (as calculated from dilution of calibrator 3), 
and linearity (as calculated from dilution of calibrator 7). Inaccuracy was defined as 
concentrations outside 20 % at the lower concentration (accuracy 80-120 %) and 15 % for the 
medium and high concentrations (accuracy 85-115 %). Imprecision was taken as a variation 
(relative standard deviation, RSD %) of greater than 15 % at all concentrations. Linearity and limit 
of detection were deemed acceptable when the measured concentration was within 15 % of the 
nominal concentration for each dilution. Carry-over was assessed by analysis of the highest 
calibrator solution and then the lowest calibrator (N = 3 in each case); the result from the first low 
concentration calibrator was then compared to the average concentration of the three low 
calibrators – a difference of < 15 % from the nominal concentration was deemed acceptable.  
Matrix effects, extraction recovery, and process efficiency (overall recovery) were calculated for 
all analytes in all matrices using pre- and post-extraction addition to a defined analyte 
concentration (Matuszewski et al., 2003).  
Initial GBO sample stability was assessed in a similar manner to that used previously (Fisher et 
al., 2013C), i.e. as a percentage of the response to that of a directly injected methanolic 
equivalent stored at -18 to -20 ºC for the same length of time. To assess long-term analyte 
stability, samples were prepared in each matrix at concentrations matching either IQC B or 
calibration solution 4 depending on the matrix type and validated at the time of preparation. 
Following storage at -18 to -20 ºC for 6 months, the samples were reanalysed and compared to 
the nominal concentration. Results with variation <15 % from nominal were considered to indicate 
analyte stability. 
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Table 3.3: Analyte concentrations. i) analyte groups and working solution concentrations; ii) calibration 
solution concentrations; and iii) IQC solution concentrations  
 
i) 
Group A    (10 mg/L working solution) Group B   (5 mg/L working solution) 
Clozapine Amisulpride 
Norclozapine Aripiprazole 
Group C   (2 mg/L working solution) Dehydroaripiprazole 
Olanzapine Fluoxetine 
Risperidone  Norfluoxetine 
9-Hydroxyrisperidone Quetiapine 
O-Desalkylquetiapine N-Desalkylquetiapine 




Calibration solution concentration (µg/L) 
1 2 3 4 5 6 7 
A 5 20 50 200 500 1000 2000 
B 2 5 20 50 150 400 800 
C 1 2 5 20 50 100 200 
 
        
iii) 
Group 
IQC concentration (µg/L)     
A B C     
A 30 300 900     
B 6 75 300     




Analyte recovery from the Oral-Eze pad was investigated by preparing a solution (100 µg/L all 
analytes) in blank oral fluid collected from two drug-free volunteers by the ‘drool’ technique. This 
solution (1 mL) was applied to Oral-Eze pads. Once the liquid was fully absorbed, the pads were 
separately immersed in Oral-Eze collection buffer (2 mL) for 1, 3, and 18 h (i.e. overnight), at 
2-8 ºC prior to the fluid being separated from the pad in the normal way and stored in 2 mL 
polypropylene tubes at 2-8 ºC until analysed. The results were compared to those obtained from 
analysis of a 1+2 dilution of the 100 µg/L solution in Oral-Eze buffer. 
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3.5.2 Preliminary extraction recovery 
To verify the suitability of the internal standards, and establish which matrix would be appropriate 
to prepare calibration standards, analyte recoveries were investigated. Recovery was established 
from the GBO oral fluid collection solution (100 µg/L all analytes including ISs, compared to a 
directly injected methanolic equivalent). The results (Table 3.4) are given as an overall 
percentage, and then given as a ratio to the corresponding IS to correct for compensation by the 
appropriate IS.  
The recovery of some analytes, in particular sulpiride and 7-hydroxyquetiapine, were not 
corrected for by the IS used. Additional ISs (dehydroaripiprazole-D8, N-desalkylquetiapine-D8, 
7-hydroxyquetipiapine-D8, 9-hydroxyrisperidone-D4 and sulpiride-D3) were therefore purchased, 
and a test solution of each IS prepared in methanol for further investigation. A specific isotope-
labelled IS was not available for O-desalkylquetiapine, however the preliminary experiment 
showed it was well compensated for by quetiapine-D8.  
All new ISs were tuned and the most suitable transitions incorporated into the instrument method 
as with the previous analytes (Table 3.1). Analyte recovery was retested, including new ISs, from 
a variety of different matrices in order to investigate potential matrices to use to prepare the 
calibration and IQC solutions. Since both collection systems rely upon an acidic buffer, the 
matrices tested were each manufacturer’s blank buffer solution, a blank oral fluid sample 
collected using each collection system from a drug-free volunteer, deionised water, and 0.1 mol/L 
hydrochloric acid (Table 3.5).  
Recoveries from each matrix were broadly comparable between the devices. However, there 
were some cases where recovery from the matrices was not equivalent, i.e. quetiapine and its 
metabolites, and sulpiride. The extraction recovery for the Oral-Eze samples was most 
comparable to that from deionised water, whereas for the GBO samples the recoveries were 
most comparable to that from 0.1 mol/L hydrochloric acid. As such, 0.1 mol/L hydrochloric acid 
and deionised water were used to prepare the calibration solutions for the GBO samples and for 
the Oral-Eze samples, respectively. The recoveries show that the blank matrices provided by 
each manufacturer gave equivalent results to the volunteer oral fluid samples. 
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Analyte Recovery Corrected for I.S 
Amisulpride 85 103 Amisulpride-D5 
Sulpiride 22 26 Amisulpride-D5 
Amisulpride-D5 83 -  
Aripiprazole 105 100 Aripiprazole-D8 
Dehydroaripiprazole 112 107 Aripiprazole-D8 
Aripiprazole-D8 105 -  
Clozapine 116 101 Clozapine-D8 
Clozapine-D8 115 -  
Norclozapine 128 108 Norclozapine-D8 
Norclozapine-D8 118 -  
Fluoxetine 106 106 Fluoxetine-D6 
Fluoxetine-D6 99 -  
Norfluoxetine 117 118 Norfluoxetine-D5 
Norfluoxetine-D5 99 -  
Olanzapine 123 101 Olanzapine-D3 
Olanzapine-D3 121 -  
Quetiapine 116 101 Quetiapine-D8 
N-Desalkylquetiapine 130 113 Quetiapine-D8 
O-Desalkylquetiapine 116 100 Quetiapine-D8 
7-Hydroxyquetiapine 80 69 Quetiapine-D8 
Quetiapine-D8 115 -  
Risperidone 120 104 Risperidone-D4 
9-Hydroxyrisperidone 114 99 Risperidone-D4 
Risperidone-D4 115 -  
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Amisulpride 64 71 69 69 71 72 
Amisulpride-D5 61 63 66 68 65 65 
Aripiprazole 102 106 104 105 97 103 
Aripiprazole-D8 107 107 101 104 101 104 
Dehydroaripiprazole 104 108 104 107 100 101 
Dehydroaripiprazole-D8 107 107 101 104 101 104 
Clozapine 105 109 111 114 107 108 
Clozapine-D8 107 113 115 117 110 108 
Norclozapine 87 92 90 94 88 91 
Norclozapine-D8 88 91 91 93 88 91 
Fluoxetine 83 88 81 89 83 85 
Fluoxetine-D6 86 86 76 81 80 84 
Norfluoxetine 111 99 110 69 67 67 
Norfluoxetine-D5 73 76 70 83 74 76 
Olanzapine 103 113 113 106 85 106 
Olanzapine-D3 101 107 112 105 83 102 
Quetiapine 105 115 117 77 90 111 
O-Desalkylquetiapine 105 109 114 88 91 107 
Quetiapine-D8 105 109 114 93 93 106 
N-Desalkylquetiapine 99 106 102 98 101 106 
N-Desalkyquetiapine-D8 94 98 95 97 93 96 
7-Hydroxyquetiapine 83 96 97 42 45 39 
7-Hydroxyquetiapine-D8 80 95 93 44 44 37 
Risperidone 103 109 111 107 102 102 
Risperidone-D4 99 106 111 107 100 105 
9-Hydroxyrisperidone 95 103 107 97 95 99 
9-Hydroxyrisperidone-D4 93 100 109 99 94 99 
Sulpiride 21 28 24 10 11 8 
Sulpiride-D3 21 27 23 10 10 7 
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3.5.3 Preparation of calibration and internal quality control solutions 
Due to the large number of analytes, intermediary working solutions were prepared for the 
analytes grouped at three different concentrations to match the predicted concentrations of the 
analytes expected in samples based on the plasma analyte concentrations (Table 3.3). These 
intermediary solutions were prepared, and the calibration and IQC solutions independently 
produced, by pipetting appropriate volumes of the stock solutions into volumetric glassware and 
making up to volume with the respective matrices before being separated into smaller portions 
and stored at -18 to -20 ºC until used. Only STD 1-4 and IQC A and B (Table 3.3) could be 
produced for norfluoxetine due to the limited availability of the reference compound leading to a 
finite volume of solution being available. 
In line with the recovery experiments, the calibration solutions for the GBO system were prepared 
in 0.1 mol/L hydrochloric acid and the IQC solutions in the GBO buffer; for the Oral-Eze system 
calibration solutions were prepared in deionised water with the IQC solutions being prepared in 
the Oral-Eze buffer. Due to the 1+2 dilution of patient oral fluid samples in the Oral-Eze collection 
system the calibration and IQC solutions were prepared at one-third of nominal to reflect the 
patient samples and make the analytical measurement as comparable as possible with the 
clinical samples and the calibration and IQC solutions. Plasma calibration and IQC solutions at 
the same concentrations were prepared in dipotassium EDTA plasma (Table 3.3). 
Full calibration curves were extracted and nominal concentrations verified for all IQCs for the 
plasma, Oral-Eze and GBO methods. 
 
3.5.4 Analyte calibration 
Calibration graphs for all analytes were linear within the calibration range, with R
2
 >0.9 for all 
methods and analytes (Figure 3-6). 
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Figure 3-6: Examples of analyte calibration curves 
 
Clozapine
Y = 0.04558+0.113485*X   R^2 = 0.9996   W: 1/X















Y = -0.0291402+0.108833*X   R^2 = 0.9983   W: 1/X















Y = 0.0197061+0.0696226*X   R^2 = 0.9994   W: 1/X


















Y = -0.0595693+0.287801*X   R^2 = 0.9968   W: 1/X

















Y = -0.034547+0.0699655*X   R^2 = 0.9963   W: 1/X


















Y = -0.138049+0.073606*X   R^2 = 0.9982   W: 1/X

















Y = -0.110844+0.14649*X   R^2 = 0.9974   W: 1/X

















Y = -0.0898213+0.106722*X   R^2 = 0.9977   W: 1/X




















 Page 74 
Figure 3-6 (cont.) 
 
Fluox-148
Y = -0.0114039+0.109679*X   R^2 = 0.9953   W: 1/X




















Y = 0.0338472+0.0731218*X   R^2 = 0.9931   W: 1/X



















Y = -0.0237293+0.090641*X   R^2 = 0.9964   W: 1/X




















Y = -0.0224864+0.0920866*X   R^2 = 0.9977   W: 1/X





















Y = -0.0219807+0.0458992*X   R^2 = 0.9971   W: 1/X



















Y = -0.0665126+0.0471419*X   R^2 = 0.9967   W: 1/X



















Y = 0.0574092+0.0858267*X   R^2 = 0.9966   W: 1/X
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3.5.5 Limit of detection, linearity and carryover 
Carryover was assessed for all analytes for all methods, and was below 15 % for all analytes. 
Limits of detection are given in Table 3.6, and show that the assigned limits of detection were 
generally higher for the Oral-Eze system method as would be expected due to the one-third 





Table 3.6: Limits of detection for each analytical method 
 
Analyte 
Limit of detection (µg/L) 
GBO system method Oral-Eze system method 
Amisulpride 5 5 
Aripiprazole 2 5 
Dehydroaripiprazole 2 5 
Clozapine 5 10 
Norclozapine 5 10 
Fluoxetine 2 5 
Norfluoxetine 2 5 
Olanzapine 2 5 
Quetiapine 2 5 
N-Desalkylquetiapine 2 5 
O-Desalkylquetiapine 2 2 
7-Hydroxyquetiapine 2 2 
Risperidone 1 2 
9-Hydroxyrisperidone 1 2 
Sulpiride 2 5 
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3.5.6 Within- and between-batch accuracy and precision 
3.5.6.1 GBO device 
Results for the accuracy and precision studies for the GBO system method are given within-batch 
(Table 3.7) and between-batch (Table 3.8). Full data are given in Appendix B. 
Aripiprazole and dehydroaripiprazole displayed significant inaccuracy (both within- and between-
batch), possibly caused by the analyte solubility and stability issues that have been described 
previously (Fisher et al., 2013B), or due to an error with production of the calibrators and IQCs. 
These issues were not further investigated since these analytes played not further part in the 
clinical study. Within-batch results were generally precise, as indicated by the low RSD%, 
however between-batch the variation became much higher. 
 
3.5.6.2 Oral-Eze device 
Results for the accuracy and precision studies for the Oral-Eze system method are given within-
batch (Table 3.9) and between-batch (Table 3.10). Full data are given in Appendix B. 
As with the GBO system method there was a large inaccuracy observed both between- and 
within-batch for aripiprazole and dehydroaripiprazole, and no further investigations were carried 
out. Fluoxetine and norfluoxetine displayed some within-batch imprecision at low concentration as 
with the GBO system method. This was taken as acceptable since clinically the difference in 
result obtained would have little meaning, and these analytes did not play a major part in the 
further study. 
For the Oral-Eze method there was a large degree of inaccuracy for a number of the analytes, 
especially at low concentration. This could be related to the lower assay sensitivity (Figure 3-5:) 
due to the one-third dilution of the solutions compared to nominal to account for the dilution of 
oral fluid samples into the collection buffer. 
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Table 3.7: Within-batch accuracy and precision for the GBO system method. 
 Results imprecise or inaccurate highlighted in bold. N = 5 
 
Nominal [analyte] (µg/L) Mean (µg/L) RSD (%) Accuracy (%) 
Amisulpride 
6 7 2.3 111 
75 70 4.6 93 
300 282 3.8 94 
Aripiprazole 
6 4 14.7 63 
75 34 2.0 45 
300 218 1.7 73 
Dehydroaripiprazole 
6 3 21.0 49 
75 32 2.1 43 
300 223 3.4 74 
Clozapine 
60 51 2.8 85 
300 275 1.6 92 
900 866 3.5 96 
Norclozapine 
60 50 4.3 83 
300 272 2.5 91 
900 836 0.9 93 
Fluoxetine 
6 6 14.5 100 
75 76 10.3 102 
300 291 14.4 97 
Norfluoxetine 
6 6 10.5 100 
75 80 5.2 107 
Olanzapine 
3 3 4.0 90 
30 26 1.1 85 
90 79 3.6 88 
Quetiapine 
6 7 6.1 110 
75 66 1.9 88 
300 278 2.1 93 
N-Desalkylquetiapine 
6 7 8.0 111 
75 68 4.9 90 
300 271 5.1 90 
O-Desalkylquetiapine 
3 3 3.2 104 
30 30 2.9 100 
90 91 1.4 101 
7-Hydroxyquetiapine 
3 3 7.1 96 
30 29 2.7 98 
90 89 3.5 98 
Risperidone 
3 3 5.3 94 
30 29 2.1 97 
90 88 1.7 97 
9-Hydroxyrisperidone 
3 3 11.7 101 
30 29 2.9 97 
90 88 4.4 98 
Sulpiride 
6 6 14.7 105 
75 85 3.3 114 
300 317 5.6 106 
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Table 3.8: Between-batch accuracy and precision for the GBO system method. 
 Results imprecise or inaccurate highlighted in bold. N = 4 
 
Nominal [analyte] (µg/L) Mean (µg/L) RSD (%) Accuracy (%) 
Amisulpride 
6 7 6.3 116 
75 71 3.3 94 
300 284 2.1 95 
Aripiprazole 
6 3 19.8 54 
75 29 17.1 39 
300 213 7.2 71 
Dehydroaripiprazole 
6 3 9.1 44 
75 29 19.2 38 
300 222 5.4 74 
Clozapine 
60 50 2.8 83 
300 285 8.8 95 
900 851 2.6 95 
Norclozapine 
60 50 3.8 84 
300 273 3.9 91 
900 850 3.6 94 
Fluoxetine 
6 6 8.0 99 
75 75 13.5 100 
300 290 1.4 97 
Norfluoxetine 
6 7 11.9 111 
75 79 11.3 105 
Olanzapine 
3 3 5.9 92 
30 26 6.9 86 
90 79 4.9 87 
Quetiapine 
6 6 3.1 105 
75 66 1.7 89 
300 276 2.0 92 
N-Desalkylquetiapine 
6 6 3.4 106 
75 67 3.9 89 
300 277 2.2 92 
O-Desalkylquetiapine 
3 3 2.3 102 
30 30 1.5 101 
90 90 1.5 100 
7-Hydroxyquetiapine 
3 3 1.4 95 
30 29 1.8 97 
90 92 13.2 102 
Risperidone 
3 3 3.2 91 
30 28 3.6 94 
90 86 2.4 96 
9-Hydroxyrisperidone 
3 3 2.5 98 
30 30 4.6 99 
90 90 5.8 100 
Sulpiride 
6 6 5.9 107 
75 85 12.6 114 
300 326 3.3 109 
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 Table 3.9: Within-batch accuracy and precision for the Oral-Eze system method. 
 Results imprecise or inaccurate highlighted in bold. N = 5 
 
Nominal [analyte] (µg/L) Mean (µg/L) RSD (%) Accuracy (%) 
Amisulpride 
6 7 4.9 113 
75 73 2.5 97 
300 299 2.8 100 
Aripiprazole 
6 11 3.7 187 
75 85 3.3 114 
300 343 4.4 114 
Dehydroaripiprazole 
6 12 2.3 199 
75 103 3.6 137 
300 404 4.8 135 
Clozapine 
60 69 2.2 115 
300 290 3.1 97 
900 925 1.6 103 
Norclozapine 
60 68 2.4 113 
300 273 3.7 91 
900 898 3.2 100 
Fluoxetine 
6 7 17.1 115 
75 68 13.9 91 
300 307 9.5 102 
Norfluoxetine 
6 8 16.8 140 
75 77 9.4 102 
Olanzapine 
3 4 3.8 142 
30 33 3.5 109 
90 99 2.9 110 
Quetiapine 
6 6 5.2 97 
75 55 2.5 73 
300 225 2.5 75 
N-Desalkylquetiapine 
6 8 7.0 133 
75 80 2.3 106 
300 337 4.8 112 
O-Desalkylquetiapine 
3 3 8.2 101 
30 29 3.4 97 
90 85 2.1 94 
7-Hydroxyquetiapine 
3 3 12.6 90 
30 24 5.2 80 
90 72 7.0 80 
Risperidone 
3 4 4.8 124 
30 31 1.3 105 
90 97 4.6 108 
9-Hydroxyrisperidone 
3 3 6.5 107 
30 32 5.0 107 
90 98 5.2 109 
Sulpiride 
6 6 14.6 107 
75 87 8.9 116 
300 347 8.3 116 
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Table 3.10: Between-batch accuracy and precision for the Oral-Eze system method. 
 Results imprecise or inaccurate highlighted in bold. N = 4 
 
Nominal [analyte] (µg/L) Mean (µg/L) RSD (%) Accuracy (%) 
Amisulpride 
6 7 3.7 116 
75 74 2.2 99 
300 305 2.1 102 
Aripiprazole 
6 11 3.2 189 
75 90 4.4 120 
300 357 3.5 119 
Dehydroaripiprazole 
6 12 3.5 200 
75 106 4.6 142 
300 411 4.0 137 
Clozapine 
60 71 2.1 118 
300 290 2.4 97 
900 935 1.9 104 
Norclozapine 
60 66 8.4 111 
300 264 10.7 88 
900 847 11.7 94 
Fluoxetine 
6 7 5.9 112 
75 77 14.2 102 
300 304 8.8 101 
Norfluoxetine 
6 9 5.4 150 
75 72 11.8 96 
Olanzapine 
3 6 31.0 187 
30 34 6.1 113 
90 99 3.2 110 
Quetiapine 
6 6 5.7 105 
75 55 3.8 74 
300 228 3.2 76 
N-Desalkylquetiapine 
6 9 7.0 143 
75 85 6.1 113 
300 356 4.4 119 
O-Desalkylquetiapine 
3 3 4.4 100 
30 27 9.4 89 
90 81 5.6 90 
7-Hydroxyquetiapine 
3 3 6.1 85 
30 24 3.3 81 
90 74 5.4 82 
Risperidone 
3 4 4.0 127 
30 32 2.1 107 
90 97 1.4 107 
9-Hydroxyrisperidone 
3 4 11.7 123 
30 33 3.2 110 
90 104 7.7 116 
Sulpiride 
6 7 9.6 114 
75 90 7.5 120 
300 342 6.2 114 
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3.5.6.3 Plasma  
The method used was the same as that previously presented (Fisher et al., 2013B; Fisher et al., 
2012B), except that fluoxetine and norfluoxetine were added (Table 3.11). Accuracy was 
acceptable for all analytes meeting the published criteria, as well as for the added analytes, 
although there was some imprecision observed within these new analytes, especially at lower 
concentration. 
 
3.5.7 Matrix effects, extraction recovery and process efficiency 
As per the method first suggested by Matuszewski et al. (2003), matrix effects (Table 3.12), 
extraction recovery (Table 3.13) and process efficiency (overall recovery; Table 3.14) were 
calculated for all analytes in all matrices, and then displayed as corrected for IS (Table 3.15). The 
majority of the variation in process efficiency was attributable to extraction recovery (Table 3.13). 
 
 
Table 3.11: Plasma method fluoxetine and norfluoxetine accuracy and precision. 
 Results imprecise or inaccurate highlighted in bold. (N = 4) 
(A) Within-assay; (B) Between-assay  
 
(A)  Nominal [analyte] (µg/L) Mean (µg/L) RSD (%) Accuracy (%) 
Fluoxetine 
6 6 19.4 107 
75 77 14.4 102 
300 305 14.2 102 
Norfluoxetine 
6 6 10.4 107 
75 68 12.9 91 
     
(B)  Nominal [analyte] (µg/L) Mean (µg/L) RSD (%) Accuracy (%) 
Fluoxetine 
6 6 14.3 101 
75 74 6.6 99 
300 298 3.4 99 
Norfluoxetine 
6 6 5.6 102 






























Amisulpride 106 102 107 122 104 107 106 122 108 
Amisulpride-D5 90 105 113 120 101 104 113 120 93 
Aripiprazole 100 99 131 112 95 90 131 112 130 
Aripiprazole-D8 102 102 111 114 101 113 111 114 110 
Dehydroaripiprazole 96 97 106 110 93 87 95 110 128 
Dehydroaripiprazole-D8 82 102 111 114 101 113 111 114 110 
Clozapine 90 91 98 104 96 83 98 104 121 
Clozapine-D8 84 105 109 115 100 113 109 115 118 
Norclozapine 109 94 102 106 96 82 102 106 108 
Norclozapine-D8 103 102 111 113 100 108 111 113 99 
Fluoxetine 106 92 101 116 114 99 101 116 100 
Norfluoxetine 103 93 106 101 105 96 94 80 85 
Norfluoxetine-D5 110 112 101 114 93 102 101 114 104 
Olanzapine 100 109 103 108 91 99 103 108 118 
Olanzapine-D8 109 107 124 126 107 123 124 126 106 
Quetiapine 98 100 106 114 93 100 99 114 101 
O-Desalkylquetiapine 105 103 114 118 99 108 114 118 128 
Quetiapine-D8 105 104 113 118 101 102 113 118 105 
N-Desalkylquetiapine 102 103 108 121 97 98 107 121 129 
N-Desalkylquetiapine-D8 104 102 115 124 102 93 115 124 100 
7-Hydroxyquetiapine 108 78 113 121 99 104 113 121 100 
7-Hydroxyquetiapine-D8 95 103 112 118 100 95 112 118 78 
Risperidone 101 102 106 108 92 114 106 108 115 
Risperidone-D4 85 104 115 118 103 123 115 118 98 
9-Hydroxyrisperidone 98 102 103 109 90 105 103 109 102 
9-Hydroxyrisperidone-D4 83 104 113 97 98 87 113 122 106 
Sulpiride 94 99 104 106 89 103 129 106 130 





























Amisulpride 73 73 80 75 79 55 62 57 64 
Amisulpride-D5 72 73 70 69 78 61 53 52 60 
Aripiprazole 108 96 73 91 95 78 51 66 70 
Aripiprazole-D8 101 103 95 95 107 69 64 65 64 
Dehydroaripiprazole 112 97 95 92 85 79 75 69 70 
Dehydroaripiprazole-D8 131 103 95 95 107 69 64 65 64 
Clozapine 121 110 108 108 103 80 71 71 78 
Clozapine-D8 136 102 99 102 112 66 69 67 71 
Norclozapine 105 109 106 106 100 80 68 74 69 
Norclozapine-D8 105 109 97 101 108 75 83 86 64 
Fluoxetine 101 108 98 100 95 95 103 93 82 
Norfluoxetine 108 102 90 109 83 57 47 60 59 
Norfluoxetine-D5 96 96 99 98 110 50 59 53 51 
Olanzapine 112 99 94 96 65 76 72 76 82 
Olanzapine-D8 109 102 98 98 108 64 66 72 84 
Quetiapine 111 100 103 100 116 36 49 48 100 
O-Desalkylquetiapine 104 97 94 97 105 38 42 48 81 
Quetiapine-D8 109 103 96 97 112 63 54 54 79 
N-Desalkylquetiapine 113 103 101 99 111 65 70 67 66 
N-Desalkylquetiapine-D8 106 105 96 102 111 53 50 46 70 
7-Hydroxyquetiapine 64 75 44 55 31 11 12 9 86 
7-Hydroxyquetiapine-D8 74 58 44 56 30 15 12 11 96 
Risperidone 106 95 94 97 114 65 66 70 84 
Risperidone-D4 129 101 97 99 109 63 69 68 84 
9-Hydroxyrisperidone 101 90 89 90 112 61 60 62 89 
9-Hydroxyrisperidone-D4 124 95 89 101 106 60 48 47 76 
Sulpiride 21 17 10 16 7 4 3 4 24 





























Amisulpride 77 74 85 92 82 59 67 70 70 
Amisulpride-D5 74 76 79 83 79 62 60 63 55 
Aripiprazole 108 94 95 102 90 70 67 74 90 
Aripiprazole-D8 108 105 105 109 108 78 71 75 71 
Dehydroaripiprazole 108 94 94 101 79 69 70 76 89 
Dehydroaripiprazole-D8 108 105 105 109 108 78 71 75 71 
Clozapine 108 100 106 113 99 66 70 75 95 
Clozapine-D8 114 107 108 117 112 74 75 77 83 
Norclozapine 111 102 108 113 97 66 69 78 75 
Norclozapine-D8 112 111 107 114 108 91 92 97 63 
Fluoxetine 107 99 99 116 108 94 104 107 82 
Norfluoxetine 111 95 96 111 87 55 44 48 50 
Norfluoxetine-D5 106 108 100 112 102 51 60 61 53 
Olanzapine 112 104 97 103 79 80 74 82 96 
Olanzapine-D8 114 109 122 123 115 79 81 91 87 
Quetiapine 109 100 109 115 108 37 49 55 101 
O-Desalkylquetiapine 109 101 107 114 104 41 48 57 104 
Quetiapine-D8 109 107 108 115 113 53 61 64 83 
N-Desalkylquetiapine 115 106 115 120 107 64 72 81 85 
N-Desalkylquetiapine-D8 115 108 111 126 113 47 58 57 70 
7-Hydroxyquetiapine 69 58 50 66 30 9 13 11 89 
7-Hydroxyquetiapine-D8 71 60 49 66 30 11 13 12 74 
Risperidone 107 97 99 105 105 74 70 76 97 
Risperidone-D4 110 105 111 117 112 78 79 80 82 
9-Hydroxyrisperidone 98 92 91 98 101 64 61 68 90 
9-Hydroxyrisperidone-D4 102 99 100 112 104 52 54 57 78 
Sulpiride 20 17 11 17 6 4 4 4 31 






























Amisulpride 104 98 108 111 103 94 111 111 126 
Aripiprazole 100 90 91 94 83 89 94 99 127 
Dehydroaripiprazole 100 90 90 93 73 88 98 101 126 
Clozapine 95 94 98 97 88 89 93 97 113 
Norclozapine 99 92 101 99 89 72 75 81 118 
Fluoxetine 107 99 99 116 108 94 104 107 82 
Norfluoxetine 104 88 96 99 85 107 73 79 95 
Olanzapine 99 95 80 84 52 101 91 90 111 
Quetiapine 100 93 100 100 95 70 80 85 122 
N-Desalkylquetiapine 100 99 104 96 95 135 124 143 122 
O-Desalkylquetiapine 100 94 98 100 92 76 78 89 125 
7-Hydroxyquetiapine 98 98 101 101 102 82 99 91 120 
Risperidone 97 93 90 90 93 95 88 95 119 
9-Hydroxyrisperidone 96 93 91 88 97 123 115 119 116 
Sulpiride 104 101 87 90 97 120 115 114 128 
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3.5.8 Analyte recovery from the Oral-Eze pad 
The Oral-Eze device relies on adsorption of the oral fluid onto a pad and then equilibration of 
analytes from the pad into the collection buffer to a consistent degree, hence the impact of 
analyte adsorption onto the pad and equilibration time was considered. 
A solution was prepared (100 µg/L, all analytes) in blank oral fluid collected by the drool 
technique (left to pool in the mouth) from drug-free volunteers. This solution was applied to the 
pad (1 mL) until all liquid was absorbed, and the pad was then submerged in the buffer for 
varying amounts of time before the pad was plunged down and the collection fluid separated 
into 2 mL tubes. These solutions were extracted and analysed, and the results compared to an 
extract from a sample where 1 mL of the solution was applied directly into the buffer without a 
pad. To minimise the impact of variation in equilibration time, and as per personal guidance 
from the Thermo technical specialist, it was decided that leaving the pad in the buffer overnight 
should be tested. Results (Table 3.16) showed that storage of the pad in the buffer solution 
enabled the analytes to equilibrate during storage since the analytes recoveries increased 
overnight (18 hours) compared to either 1 hour, or 3 hours. In addition, the results from oral fluid 
from two different sources were broadly in agreement, suggesting that whilst it was possible that 
there could be some variation dependent on the features of each individuals oral fluid (i.e. 
viscosity, pH etc), these effects were minimised by the dilution into the buffer solution. 
The clinical samples were therefore stored in the refrigerator overnight, and then the fluid was 
plunged from the pad and the collected fluid stored in 2 mL polypropylene tubes at -18 to -20 ºC 
until analysed. 
Due to the continued ongoing adsorption of analytes onto the pad even after equilibration, as 
indicated by the poor recovery of some analytes, clinical results from the analysis of samples 
collected using this system were corrected by the factor determined as the overall recovery in 
order to compensate for the fact the that calibration solutions did not undergo such losses. As 
such, the results were divided by the overall overnight recoveries described in Table 3.16 – for 










Table 3.16: Recovery of the analytes (%) off the pad when stored in the buffer prior to being plunged off for varying times compared to a solution not applied to the pad.  
Overnight was 18 hours. (N=6) 
 
Analyte 
1 Hour recovery (mean ± SD) 3 Hour recovery (mean ± SD) Overnight recovery (mean ± SD) 
Source 1 Source 2 Overall Source 1 Source 2 Overall Source 1 Source 2 Overall 
Amisulpride 78 ± 4.5 73 ± 4.1 75 ± 4.8 84 ± 3.3 80 ± 5.2 82 ± 4.8 83 ± 4.1 83 ± 3.8 83 ± 3.8 
Aripiprazole 36 ± 3.6 31 ± 2.4 34 ± 3.8 35 ± 3.4 32 ± 2.0 33 ± 3.1 38 ± 4.6 42 ± 3.9 40 ± 4.6 
Dehydroaripiprazole 35 ± 4.5 32 ± 4.5 34 ± 4.5 35 ± 2.5 33 ± 1.8 34 ± 2.3 36 ± 5.1 41 ± 2.5 38 ± 4.4 
Clozapine 52 ± 2.2 50 ± 4.5 51 ± 3.6 59 ± 2.1 62 ± 5.5 61 ± 4.4 63 ± 5.8 75 ± 4.3 69 ± 8.3 
Norclozapine 49 ± 2.4 40 ± 3.7 44 ± 5.8 51 ± 1.9 49 ± 7.8 50 ± 5.5 60 ± 3.9 60 ± 3.8 60 ± 3.7 
Fluoxetine 45 ± 10 28 ± 8.1 36 ± 12.5 44 ± 5.8 30 ± 13.1 37 ± 12.3 63 ± 17.1 48 ± 15.1 56 ± 17.3 
Norfluoxetine 27 ± 3.7 25 ± 6.1 26 ± 4.9 32 ± 2 31 ± 9.1 31 ± 6.3 42 ± 8.3 43 ± 5.7 42 ± 6.8 
Olanzapine 89 ± 7.7 90 ± 11.8 89 ± 9.5 99 ± 4.1 89 ± 6.4 94 ± 7.0 88 ± 5.6 97 ± 7.4 92 ± 7.9 
Quetiapine 69 ± 3.0 59 ± 7.4 64 ± 7.7 74 ± 3.0 65 ± 4.4 70 ± 5.9 77 ± 6.5 73 ± 4.3 75 ± 5.6 
N-Desalkylquetiapine 51 ± 2.8 52 ± 5.0 52 ± 3.9 55 ± 1.7 61 ± 6.6 58 ± 5.3 63 ± 5.9 67 ± 6.0 65 ± 6.0 
O-Desalkylquetiapine 64 ± 6.6 56 ± 7.9 60 ± 8.1 65 ± 4.5 67 ± 4.5 66 ± 4.3 76 ± 14.2 82 ± 10.3 79 ± 12.3 
7-Hydroxyquetiapine 75 ± 8.6 60 ± 16 68 ± 14.4 83 ± 8.8 76 ± 18 79 ± 14 83 ± 10.4 75 ± 25.9 79 ± 19.2 
Risperidone 72 ± 3.2 64 ± 5 68 ± 5.9 79 ± 1.9 72 ± 9.3 75 ± 7.3 81 ± 5.8 77 ± 5.0 79 ± 5.7 
9-Hydroxyrisperidone 81 ± 5.5 77 ± 9.8 79 ± 7.8 84 ± 3.3 86 ± 6.0 85 ± 4.8 85 ± 7.0 95 ± 6.6 90 ± 8.3 
Sulpiride 62 ± 13 70 ± 8.1 66 ± 11.2 77 ± 8.2 80 ± 11.5 79 ± 9.6 74 ± 8.2 64 ± 7.4 69 ± 9.1 
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Table 3.17: Analyte correction factor for Oral-Eze collection system clinical samples. 
 

















3.6 Analyte stability 
3.6.1 Initial analyte stability investigation: GBO system 
Analytes in the GBO collection fluid were stable at -18 to -20 ºC and at 8 to 10 ºC for 8 weeks, 
but at ambient temperature (20 ºC; Table 3.18) olanzapine declined at 2 weeks, and 
9-hydroxyrisperidone at 5 weeks, with norclozapine possibly starting to decline at 8 weeks. In 
the course of the clinical trial, the maximum time that the samples were to be stored refrigerated 
was overnight, and storage at room temperature will be only for hours, therefore the analytes 
are stable within the required times under the appropriate conditions. Longer-term stability 
studies for samples stored at -18 to -20 ºC were then undertaken to include the Oral-Eze buffer 
and other pertinent matrices.  
3.6.2 Stability in the GBO and Oral-Eze systems and plasma 
Samples were prepared at concentrations (Table 3.3) matching either STD 4 (for 0.1 mol/L 
hydrochloric acid, deionised water and plasma) or IQC B (for GBO and Oral-Eze buffers) and 
analysed at the time of preparation. Following storage at -18 to -20 ºC for 6 months, the 
samples were reanalysed and compared to the nominal concentration (Table 3.19). 
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Table 3.18: Analyte instability when stored in the GBO buffer at ambient temperature compared to a 
methanolic equivalent (%; N = 3) 
 
Analyte 1 day 2 days 3 days 1 week 2 weeks 3 weeks 5 weeks 8 weeks 
Amisulpride 0 -3 -1 -1 -3 -1 -2 -4 
Aripiprazole 2 -1 2 4 -2 -3 5 -8 
Dehydro-
aripiprazole 
3 -2 2 1 -2 -4 -2 -13 
Clozapine -1 -7 1 -4 -9 -8 -12 -6 
Norclozapine -6 -10 1 -5 -11 -4 -15 -16 
Fluoxetine 2 -5 0 6 -1 -1 -6 8 
Olanzapine 0 -2 -1 -9 -45 >100 >100 >100 
Quetiapine 0 -4 -1 -2 -8 -4 -5 0 
N-desalkyl-
quetiapine 
-4 -7 2 -2 -10 -3 -5 -10 
7-Hydroxy-
quetiapine 
-3 2 -8 -8 -3 -6 -7 -9 
O-Desalkyl-
quetiapine 
-5 -4 1 -4 -8 -7 -11 -3 
Risperidone -2 -3 1 -3 -10 -3 -6 -6 
9-Hydroxy-
risperidone 
1 -1 1 -1 -13 -13 -28 -55 
Sulpiride -3 -2 -10 -2 2 4 11 3 
 
Table 3.19: Analyte instability in different matrices when stored at -18 to -20 ºC for 6 months.  












Amisulpride -8 6 -6 0 -1 
Aripiprazole 9 0 -7 4 -6 
Dehydroaripiprazole 11 56 -11 -2 4 
Clozapine 2 -6 -12 -2 -6 
Norclozapine -6 13 -7 6 -7 
Fluoxetine 8 1 -5 10 34 
Olanzapine -4 14 -4 -2 -8 
Quetiapine -5 9 0 -9 1 
N-Desalkylquetiapine -14 4 -4 -3 -14 
O-Desalkylquetiapine -4 -4 -3 -4 3 
7-Hydroxyquetiapine -10 11 0 8 -1 
Risperidone -6 2 5 -7 -5 
9-Hydroxyrisperidone -6 -10 -2 -3 -14 
Sulpiride -9 -1 -5 10 -7 
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The analytes were stable over the time period studied; the only results that were outside of 
15 % variation from nominal were those analytes for which there was significant imprecision in 
the assay, and these results showed an increase, not decrease, in measured analyte 
concentration. 
3.7 Discussion 
There have been few papers that study the application of oral fluid in the TDM of antipsychotics 
(Dumortier  et al., 1998; Langel et al., 2014; Patteet et al., 2016; Saracino et al., 2010; Fisher et 
al., 2013B). Broadly, these studies have been undertaken using LC-MS/MS as a modification of 
existing plasma methodologies, in order to attain sensible limits of detection and good analyte 
selectivity. This process was followed with this work. Two published plasma analytical methods 
were combined (Fisher et al., 2013B; Fisher et al., 2012B), clozapine and norclozapine were 
included, and fluoxetine and norfluoxetine were added. The method developed allowed 
extraction of all relevant analytes and detection and quantification within a single procedure. 
The sample preparation technique was then optimised to enable extraction from the buffered 
oral fluid samples and also work to concentrate the analytes to attain the required sensitivity.  
The methods take into account the dilution of the analyte in the Oral-Eze buffer, and 
compensates for the analyte adsorption onto the pad. For the GBO method, a separate 
spectrophotometric assay was developed to quantify tartrazine within the collection solution, 
and will be used to calculate the concentration of analyte in the oral fluid. 
The oral fluid methods developed were assessed as to whether they were fit-for-purpose. 
Aripiprazole and dehydroaripiprazole displayed significant inaccuracy and imprecision in both 
methods, possibly related to the poor analyte stability and solubility identified previously (Fisher 
et al., 2013B) as the variation within-batch was less compared to between different batches. 
Fluoxetine and norfluoxetine also displayed some imprecision at the lower concentrations in the 
GBO method, possibly related to this being at the limit of sensitivity for these analytes. In the 
Oral-Eze method, precision was much poorer for fluoxetine and norfluoxetine, above what 
would generally be classified as acceptable; in addition the Oral-Eze method showed greater 
inaccuracy for a number of analytes, especially at the lower concentrations. Thus, accuracy and 
precision overall were acceptable for the analytes, except for aripiprazole and fluoxetine. Initial 
plans for the creation of the clinical trial were to obtain samples in collaboration with a local 
mental health hospital from a variety of patients prescribed the relevant medications, including 
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children prescribed fluoxetine. However, ethics permission was not attained within the required 
timeframe, and therefore an alternative source of patient samples was found in an adult 
inpatient and outpatient facility in South Africa with full ethics approval. This therefore affected 
the subset of samples collected based on the different selection of prescribed drugs in the 
patient cohort. As such, the  analytes for which the assessment into methodological robustness 
did not meet the criteria set (aripiprazole and fluoxetine) did not form a large part of the clinical 
study undertaken to establish the relationship between plasma and oral fluid, since neither 
fluoxetine nor aripiprazole were prescribed significantly (or at all) in the patient cohort for whom 
ethics approval was obtained.  As such, the methods were fit-for-purpose for the single clinical 
trial on which it would be used without these analytes meeting the assessment criteria, and no 
further investigation was undertaken. Process efficiency (overall recovery) was investigated 
according to the method of Matuszewski et al. (2003). Virtually no ion suppression or 
enhancement was identified for any of the analytes in any matrix. This was likely due to the fact 
that LLE is a very efficient method of sample preparation with specific analysis by pH-
dependent SCX chromatography, and although the extraction recovery varied significantly 
between analytes and collection device, this was in general well compensated for by the 
corresponding IS.  
Both collection devices investigated relied on the sample being stored in an acidic buffer, and 
therefore this is likely to help stabilise the basic compounds in question. Short term stability was 
investigated within the GBO buffer, and showed that all analytes were stable when stored for 
8 weeks at 8 to 10 ºC and at -18 to -20 ºC. When stored at ambient temperature (20 ºC), 
olanzapine was shown to decline after 2 weeks and 9-hydroxyrisperidone at 5 weeks. The 
stability was therefore acceptable within the required time frame for which samples would be 
stored for the purposes of the clinical application (overnight refrigerated and maximum of a few 
hours at room temperature). Samples were prepared in each matrix and stored for a longer time 
period (6 months) at -18 to -20 ºC to cover the period of the study for sample collection and 
analysis and represent the longest time the clinical samples would be stored prior to analysis. 
The results of this study showed that no analytes in any matrix declined by more than 15 %. 
Those analytes for which variation from the nominal was outside of 15 % displayed an increase 
in concentration and were analytes for which the normal batch precision was poor, and 
therefore this variation in response is likely to be analytical variation.  
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Further investigation could be undertaken to enhance the understanding of between-individual 
and between-pad variability in the extraction of the analytes from the Oral-Eze pad. For 
example, a greater number of volunteer analyte-free donors could be tested in order to assess 
the impact the analyte adsorption onto the pad has on the observed SD (Table 3.16). In 
addition, a back-calculation experiment could be undertaken to ensure the application of the 
correction factor is appropriate; this could take the form of applying 1 mL of solution of known 
concentration in drool oral fluid to the pad in lieu of collecting from the cheek of a patient, but 
then follow the collection and analysis process as per the protocol. The calculated concentration 
from this solution can then be used to verify the factor that was applied to patient samples, and 
quantify the variability in recovery between different pads. 
Overall this chapter presents the development and assessment of two oral fluid assays, and the 
plasma assay. The assays were shown to be fit-for-purpose, when taking into account that 
aripiprazole and fluoxetine analysis was not integral to the clinical trial being undertaken.  
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Chapter 4.  Potential role of oral fluid in antipsychotic TDM: 
Clinical study  
4.1 Introduction 
4.1.1 Oral fluid  
The composition of oral fluid, which contains saliva (the largely water-based fluid secreted by 
the salivary glands) as well as proteins, enzymes, electrolytes and cells, can vary dramatically 
over the course of a day based on circadian rhythm, degree of hydration, and physiological 
responses such as stress and oral sensory stimulation (e.g. chewing), and may also be affected 
by genetics and medication (Aps and Martens, 2005). For a drug to enter saliva it must pass 
from the bloodstream through the capillary wall by passive or active diffusion, or ultrafiltration. 
Passive diffusion is the most common route of transfer, hence concentrations of drugs in oral 
fluid may be affected by the oral fluid pH at the time of collection, and by drug pKa, lipid 
solubility, molecular weight, unbound concentration in plasma, and salivary binding protein 
concentration (Aps and Martens, 2005; Drummer, 2008; Patsalos and Berry, 2013). One study 
in 20 healthy volunteers found unstimulated saliva pH to be 6.8 ± 0.3, but high salivation rates 
produced more alkaline pH, and low salivation rates more acidic pH with lower buffering 
capacity (Bardow et al., 2000); a similar study found the mean pH across all sites in the mouth 
to be 6.78 ± 0.04, with the mean pH specifically in the cheek area of 6.28 ± 0.36 (Aframian et 
al., 2006).  
Further potential variables in the collection of oral fluid samples include stimulation of saliva 
production during sample collection, variation in the volume of sample taken, inhomogeneity of 
the oral fluid collected, and oral cavity contamination with tablet residue. A study to quantify 
different salivary proteins in oral fluid using a number of commercially available collection 
devices showed significant differences in both the analyte concentrations and salivary flow rates 
between the different collection techniques (Topkas et al., 2012), in turn showing that each 
collection device may collect a non-comparative oral fluid sample. 
Comparison of commercially available oral fluid collection devices and the recovery and stability 
of a number of different drugs of abuse showed that there is a large variability in the suitability of 
the varying collection devices (Crouch et al., 2008; Langel et al., 2008). The authors of one 
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study recommend thorough testing prior to utilising any collection device to ensure that the 
recovery and stability of the analytes in question meet requirements, where limitations can 
include contamination of the instrumentation from additives in the collection device such as the 
buffer; they concluded that devices which rely on a buffer overall had improved recovery and 
stability, and the GBO device performed well in all areas of testing (Langel et al., 2008). 
Moreover, use of a collection solution could also facilitate oral fluid sampling in patients that 
produce small quantities of saliva. Dilution of the (normally viscous) oral fluid in the collection 
solution could help accurate pipetting. On the other hand, dilution of the oral fluid collected may 
limit sensitivity. 
Oral fluid has been used for TDM of some weakly acidic/neutral drugs such as anticonvulsants 
(Patsalos and Berry, 2013), as well as regularly in roadside devices for drugs of abuse testing 
(Crouch et al., 2004; Crouch et al., 2008; Langel et al., 2008; Langman et al., 2007; Willie et al., 
2009). However, for protonatable (basic) drugs, it is likely that changes in oral fluid pH during 
sample collection affect the presumed plasma:oral fluid equilibrium (Horning et al., 1977; Kato 
et al. 1993).  
4.1.2 SGAs in oral fluid 
Many of the SGAs are basic drugs (pKa ~8-9; Table 1.1), therefore changes in oral fluid pH may 
impact the diffusion of these analytes across the salivary glands and into oral fluid. In addition, 
many of the SGAs act on the adrenergic and cholinergic systems, which may in turn affect the 
composition of oral fluid compared to healthy individuals (Taylor et al., 2015). 
In oral fluid collected via the drool method (unstimulated oral fluid) in 90 patients prescribed a 
variety of SGAs, there was a relatively poor correlation (R
2
 = 0.3–0.7) between the plasma and 
oral fluid concentrations measured (Fisher et al., 2013A). Hence, unstimulated oral fluid was 
unable to predict plasma concentrations (Fisher et al., 2013A; Patteet et al., 2015). 
In a small study of risperidone concentrations in paediatrics using oral fluid collected by 
Sarstedt Salivette (which will stimulate salivary flow to some degree) there was a good 
correlation (R
2
 = 0.93) between plasma and oral fluid risperidone concentrations when plotted 
on a logarithmic scale (Aman et al., 2007). However, other studies have shown poorer 
relationships, and wide between-patient variability between plasma and oral fluid for both 
risperidone and 9-hydroxyrisperidone concentrations as well as some other antipsychotic drugs 
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(Flarakos et al., 2004; Saracino et al., 2010; Mandrioli et al., 2011; Patteet et al., 2016). The 
wide variability reported in these studies is analogous to results from work on other basic 
analytes, including antidepressants and some drugs of abuse (de Castro et al., 2008; Wille et 
al., 2009). 
Whilst the existing limited available information overall show a relatively poor correlation 
between plasma and oral fluid concentrations of the analytes of interest, there may be some 
potential for applying oral fluid measurement if the between-patient and between-collection 
variation in the plasma:oral fluid ratio can be minimised. One possible explanation is variation in 
salivary pH during sample collection affecting these protonatable basic analytes. Use of a 
buffered oral fluid collection system may reduce the variability in oral fluid pH and thus improve 
the relationship between oral fluid and plasma analyte concentrations of basic analytes both 
between collections and between individuals, as well as potentially improving analyte stability 
(Langel et al., 2008). 
4.1.3 GBO oral fluid collection device 
The GBO collection device relies on holding a collection buffer in the mouth that will buffer the 
oral cavity to a defined pH during collection (approx. pH 4-6; Greiner Bio One, 2011). This 
means that theoretically all samples are collected and maintained under the same conditions 
irrespective of between-collection and between-individual variation in salivary pH and flow-rate. 
The amount of oral fluid can be accurately quantified by measuring the degree of dilution of 
tartrazine dye contained within the collection buffer, as discussed in Chapter 3. Correcting the 
analyte result quantified in the collection fluid by the amount of oral fluid contained within the 
collection fluid enables accurate determination of the concentration of analyte present in oral 
fluid.  
Limitations with this collection device including potential contamination of the sample from drug 
adsorbed onto the teeth are the same as with all oral fluid collections. However, in addition this 
device is unsuitable for use in patients with intolerance to aspirin or benzoic acid and in 
asthmatic patients due to the presence of, and therefore potential allergic response to, 
tartrazine (Greiner Bio One, 2011). Analyte stability has also been identified as an issue for the 
drugs of interest in unmodified oral fluid samples (Fisher et al., 2013C), therefore the impact of 
the sample being stored within a buffered solution prior to analysis had to be investigated 
(Chapter 3). 
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This collection device has been used in a wide variety of published applications including early 
detection of herpes simplex virus (Lackner et al., 2010), extraction of salivary DNA for the 
diagnosis of genetic disorders (Paar et al., 2014), investigation of salivary biomarkers 
chromogranin A and amylase in periodontitis (Haririan et al., 2012), quantification of codeine 
(Coucke et al., 2015), and investigation into detection of metamfetamine enantiomers following 
administration of a decongestant nasal inhaler (Newmeyer et al., 2015). However, there has 
been no previous detailed study in its use for the TDM of basic drugs. 
4.1.4 Oral-Eze oral fluid collection device 
The Oral-Eze device consists of a collection pad that is held in the mouth against the cheek until 
the indicator on the handle turns blue to indicate that 1 mL oral fluid has been collected (or at a 
maximum of 10 minutes). The pad is then detached into a tube which contains 2 mL of a buffer 
(approx. pH 6) for storage until analysis (Thermo Fisher Scientific, 2013; Chapter 3).  
This collection device does not collect oral fluid under defined pH conditions; however, it 
theoretically collects a defined oral fluid volume in a stimulated method from a fixed part of the 
mouth (cheek), so this may be able to counteract the variation in salivary pH. The presence of 
the buffer post-collection may improve analyte stability on storage. Limitations include the 
possible variability of 1 mL collection volume, and the need to consider analyte adsorption to the 
pad affecting the equilibrium between the collected oral fluid on the pad and the buffered 
solution that is analysed. 
Published applications of this collection device include quantifying cocaine and 
benzoylecgonine following intravenous cocaine administration (Ellefson et al., 2016) and 
investigation into the concentrations and stability of cannabis and metabolites in oral fluid 
samples (Anizan et al., 2015; Desroisiers et al., 2014; Samano et al., 2015). 
4.1.5 Aims of the chapter 
Little work has been undertaken to apply oral fluid collection devices to TDM of antipsychotic 
drugs. Theoretically use of a buffered collection device should minimise variations in oral fluid 
pH during sample collection, and hence may minimise the impact of this variable on the use of 
oral fluid for the TDM of basic drugs. 
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A clinical trial was set up in conjunction with Stellenbosch University following full ethical 
approval (Appendix A) to obtain oral fluid and plasma samples from patients prescribed 
clozapine along with other relevant drugs.  
This chapter will present the results from paired sets of plasma and oral fluid samples collected 
using both oral fluid collection devices. Data analysis will be undertaken to investigate whether 
use of the GBO system minimises between-patient and between-collection variability in the 
relationship between plasma and oral fluid analyte concentrations, as compared to post-
collection storage in buffer.  
4.2 Materials and methods 
4.2.1 Ethics 
Ethics was applied for and granted by the Health Research Ethics Committee for Stellenbosch 
University, South Africa (reference S13/11/227), for the collection of oral fluid and plasma in 
patients prescribed clozapine (Appendix A).  
Patient consent was required prior to collection of samples (Appendix A), and the patients’ 
doctor was required to agree that the patient was competent to give consent.  
Patients were eligible if they were over 18, did not suffer from aspirin or benzoic acid allergy or 
have a history of asthma, and if they were prescribed the tablet formulation of clozapine; 
patients taking the suspension formulation were not eligible due to the risk of drug adsorption 
onto teeth. Repeat samples from the same patient were permitted provided there was at least 
one day between collections.  
Full protocols used during the preparation and collection of samples are given in Appendix A. 
Collection of oral fluid samples was undertaken according to the manufacturer’s guidelines 
(Greiner Bio One, 2011; Thermo Fisher Scientific, 2013).  
4.2.2 Sample collection 
Patients were not permitted to eat or drink for 30 and 10 min, respectively, prior to oral fluid 
collection. The first sample collected was using the Oral-Eze device held against the side of the 
cheek until the indicator turned blue, or at 10 min. The pad was dispensed in the collection 
buffer and mixed. Following this, the GBO sample was collected, where the patient rinsed their 
mouth with the wash solution, then held the collection buffer in the mouth for 2 min prior to 
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being spat into the beaker and collected into the collection tube which was stored at -18 ºC to 
-20 ºC until analysis. Finally, blood was taken into a BD dipotassium ETDA tube (at least 3 mL). 
Plasma was separated off (1500 g, 5 mins) and stored in polypropylene tubes at -18 ºC to -20 
ºC until analysis. After overnight storage, the pad was plunged from the Oral-Eze buffer, and the 
buffer collected into 2 mL tubes and stored at -18 ºC to -20 ºC with the other 2 samples. All 
three sets of samples were labelled with the trial sample ID and stored together in a labelled 
bag. At the end of patient sample collection, all sample sets were sent together by courier on 
dry ice to the Toxicology Unit where they were stored at -18ºC to -20 ºC until analysed. Patient 
age and sex, time sample taken post-dose, and drug dosing schedules were collated for 
clozapine and other relevant co-prescribed medications, and stored anonymised under the trial 
patient and sample ID. 
4.2.3 Analytical methods 
The analytical methods used were those as described in Chapter 3. Antipsychotic 
concentrations calculated from the LC-MS/MS method described had to be corrected for the 
recovery from the pad for the Oral-Eze (as per section 3.5.8) and for the GBO device corrected 
for the volume of oral fluid within the collection fluid as calculated by the tartrazine concentration 
(as per section 3.3.3). Assay performance matched during the assessment, and all IQCs were 
within accepted limits for analytes that were measured in patient samples.  
4.2.4 Statistical methods 
Statistical analysis was undertaken using Excel Analyse-It (v2.30 Excel 12+) and SPSS 
(Statistics v23), according to the protocols set out in Chapter 2.2.2. 
 
4.3 Patient demographics 
Overall, 200 sets of samples (only 198 GBO samples) were collected from 112 participants; of 
these participants 31 provided a single set, 74 provided two sets and 7 provided three sets. Full 
patient demographics are given in Table 4.1.  
The other relevant medication dosage regimes were also recorded, and the results for these 
samples collated. For each sample set, all three sample types were collected (plasma, GBO 
and Oral-Eze), except in two cases where the GBO system was not collected. 
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4.4 GBO oral fluid content 
A total of 198 GBO samples were received; the median oral fluid content was 52 % (range 13-








 percentiles as 22, 37, 63 and 80 %, respectively. The oral 
fluid content of the collection fluid was not normally distributed (Shapiro Wilk 0.981, p<0.01), 
although the plot shows a good distribution especially in the central results, and there was a 
slight non-significant trend towards a lower oral fluid content with increasing age (Figure 4-1). 
The influence of independent variables (age, sex and clozapine dose) on oral fluid content was 
investigated by regression analysis. Model strength was very low; hence, oral fluid content in 
the GBO collection fluid could not be predicted by age, sex or clozapine dose. Within-patient 
variability in oral fluid content was investigated in three separate samples from 7 patients. The 
results of these samples (Table 4.2) show some variability between collections, even from the 
same patient, therefore the presence of the buffer in-mouth does not completely reduce 
between-collection variability in the oral fluid collected.  
 
Table 4.1: Patient demographics of collected oral fluid sample sets 
 
Replicates 
Number Age (median, range) 
Male Female Male Female 
First 96 16 47 (21 - 65) 44 (21 – 65) 
Second 71 10 46 (22 - 64) 44 (21 – 65) 
Third 6 1 40 (27 – 49) 34 
TOTAL 173 27 47 (21 – 65) 44 (21 – 65) 
 






Oral fluid content (%) RSD 
(%) First sample Second sample Third sample 
Male, 47 119, 56 58 56 38 21 
Male, 47 5, 170 55 63 60 7 
Male, 29 14, 7 67 69 80 9 
Male, 27 14, 7 48 54 45 10 
Female, 34 14, 7 57 71 78 15 
Male, 34 14, 7 75 72 36 35 
Male, 49 14, 7 77 69 69 6 
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Figure 4-1: Oral fluid content in the GBO patient samples 
a) Normal fit distribution for GBO oral fluid content in males and females; b) Breakdown of oral fluid 
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4.5 Clozapine and norclozapine 
The median dose was 400 (range 50–800) mg/d. Median sampling time post-dose was 
13 (range 11–26) h, with 16 samples not having a specific collection time recorded (minimum 
10 h post-dose). Clozapine dosage was once-daily (N = 78); twice-daily (N = 114); and thrice-
daily (N = 8). 
Clozapine and norclozapine were not detected in plasma and in both oral fluid samples from a 
male outpatient aged 28 yr (prescribed clozapine dose 400 mg/d). Fourteen days previously his 
plasma clozapine and norclozapine were 0.34 and 0.13 mg/L, respectively. His relapse having 
become apparent, hospital admission and re-titration were arranged promptly. 
 
4.5.1 Correlation between sample types 
The full results are summarised in Table 4.3. Correlations between plasma and both oral fluid 
results were similar between clozapine and norclozapine for GBO and Oral-Eze compared to 
plasma (0.74 - 0.79), whereas those between both oral fluid collection devices were slightly 
higher for clozapine and norclozapine (0.84 and 0.85, respectively; Table 4.4; Figure 4-2; Figure 
4-3; and Figure 4-4). 
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Table 4.3: Clozapine and norclozapine concentrations in plasma and in oral fluid. 
(a) summary data; (b) between sample-type ratios 
 
(a) 














Minimum <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
25
th 
percentile 0.25 0.17 0.21 0.11 0.08 0.14 
Median 0.43 0.32 0.40 0.20 0.15 0.26 
75
th 
percentile 0.86 0.62 0.71 0.32 0.27 0.43 
Maximum 2.30 1.73 2.72 1.59 0.98 1.19 
Mean 
3 






























Minimum 0.44 0.33 0.15 0.38 0.23 0.15 
25
th 
percentile 0.94 0.85 0.63 0.94 0.57 0.46 
Median 1.47 1.19 0.79 1.35 0.79 0.57 
75
th 
percentile 2.11 1.69 1.11 2.15 1.09 0.74 
Maximum 10.15 9.13 4.08 6.76 4.98 2.19 
Mean
3 
(SD) 1.75 (1.21) 1.39 (0.97) 0.91 (0.48) 1.64 (1.01) 0.92 (0.56) 0.63 (0.30) 
1
 N = 200; 
2
 N = 198; 
3










Plasma:GBO Plasma:Oral-Eze GBO:Oral-Eze 
Clozapine 0.78 * 0.79 * 0.84 * 
Norclozapine  0.74 * 0.79 * 0.85 * 
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Figure 4-2: Plot of oral fluid and plasma concentration correlations for clozapine and norclozapine.  
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Figure 4-3: Plot of oral fluid concentration correlations for clozapine and norclozapine.  












































































Figure 4-4: Summary patient clozapine results comparison between the difference matrices. 
(a) clozapine, (b) norclozapine, (c) norclozapine MR ratio. Box = median and inter-quartile range, whiskers = 95% CI; paired t-test p-value given between each dataset for each 
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There was a significant difference between males and females (Figure 4-5) in the ratio of 
plasma:Oral-Eze concentrations for both clozapine and norclozapine, and in the plasma 
clozapine concentration. However, plasma norclozapine concentrations and all variables 
including dose (p = 0.76) and oral fluid content (p = 0.68) were not significantly different 
between males and females. 
 
4.5.2 Regression analysis 
Regression analyses were undertaken for both clozapine (Table 4.5) and norclozapine (Table 
4.6) to investigate the influence on oral fluid concentrations of independent variables age, sex, 
clozapine dose, time since last dose, the GBO oral fluid content. GBO oral fluid content was 
included for the regression the Oral-Eze studies as well as the GBO samples in case this 
variable could be used as a surrogate marker for salivary flow rate. The difference in plasma 
compared to oral fluid clozapine and norclozapine concentrations was also investigated, to see 
if there was a proportional impact of the plasma concentration on the oral fluid result. 
Plasma analyte concentration was the most relevant variable in predicting the oral fluid 
concentration for both devices, explaining between 60 % and 70 % of the variation, although 
age and clozapine dose were also significant. For clozapine, for an increase in plasma 
concentration of 1 mg/L, there was a predicted increase in 0.53 and 0.66 mg/L for GBO and 
Oral-Eze concentrations, respectively. For norclozapine, an increase in plasma concentration of 
1 mg/L predicted an increase of 0.49 and 0.65 mg/L for GBO and Oral-Eze, respectively. The 
model strength for these regression analyses were low as would be expected since there was 
wide variability in the results (Figure 4-2).  
The difference in plasma:oral fluid concentration for clozapine and norclozapine was not reliably 
modelled since the result predicted by the equation only displayed 15-21 % correlation to the 
observed result, as expected from the poor correlation between the plasma:oral fluid 
concentration difference and age, dose and plasma analyte concentration (Figure 4-6, Figure 
4-7 and Figure 4-8, respectively).  
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Figure 4-5: Clozapine and norclozapine concentrations between males and females, and the ratio in 
plasma:Oral-Eze concentrations. 
Box = median and inter-quartile range, whiskers = 95% CI; paired t-test p-value given between each 
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Age 1.22 0.77, 1.67 0.35 <0.001 
Clozapine dose  
(100 mg/d) 


















Age 1.24 0.66, 1.81 0.28 <0.001 










Excluded GBO oral fluid content (p=0.76), time since last dose (p=0.12), sex (p=0.04) 
* model and predictors explained in Section 2.2.2.1 
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0.65 0.54, 0.77 0.59 <0.001 
Clozapine dose  
(100 mg/d) 





















Age 1.44 0.94, 1.94 0.37 <0.001 
Clozapine dose  
(100 mg/d) 


















Age 1.69 0.91, 2.48 0.28 <0.001 






(constant) -44.3 -86.2, -2.3 - 0.04 
Excluded GBO oral fluid content (p=0.68), time since last dose (p=0.43), sex (p=0.31) 
* model and predictors explained in Section 2.2.2.1 
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Figure 4-8: Plot of difference in plasma:oral fluid concentration and plasma concentration correlations for 
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For both oral fluid devices, clozapine concentrations were predicted to increase by 0.05 mg/L 
for an increase in 10 years of age, and norclozapine concentrations by 0.03 mg/L, although the 
relevance of age was low in the models. Age was more relevant to the difference in plasma:oral 
fluid concentrations, where with an increase in age the difference in plasma:oral fluid 
concentrations increases, although when plotted graphically (Figure 4-6) this was due to greater 
degree of variability in the plasma:oral fluid concentration difference of older patients. 
Clozapine dose was not highly relevant for predicting clozapine or norclozapine concentrations 
in either oral fluid device. Relevance was slightly higher for clozapine dose predicting the 
difference in analyte plasma:oral fluid concentration, but was still low as shown in the poor 
correlation graphically (Figure 4-7). 
 
4.6 Amisulpride  
Twenty-three patients were co-prescribed amisulpride [18 male, aged (median, range) 42 (21–
64) yr and 5 female, aged 34 (29–62) yr]; 5 participants provided a single set, 17 provided two 
sets and 1 provided three sets, giving 42 amisulpride sample sets in total. The median (range) 
amisulpride dose was 400 (50–1000) mg/d. Time since last dose was known for 31 samples, 
median (range) 13 (11–18) hours, and dosage was split once daily in four instances, twice daily 
in 33 instances, and was not known for five samples. 
 
4.6.1 Correlation between sample types 
The full results are summarised in Table 4.7, which gives the mean and median amisulpride 
concentrations in each matrix, as well as the ratio between the matrices. 
There was a clear outlier in the GBO results (Figure 4-9; GBO = 1827 µg/L, plasma = 735 µg/L, 
Oral-Eze = 596 µg/L), which was excluded from further analysis of the data. There was a 
significant difference between the median amisulpride GBO and plasma results, and between 
the GBO and Oral-Eze results; however, the plasma and Oral-Eze results were comparable 
(Figure 4-10). The correlations between the plasma and both sets of oral fluid results were 
similar (Table 4.8, Figure 4-11). 
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Minimum 40 16 29 0.89 0.34 0.18 
25
th 
% 272 86 244 1.77 0.81 0.32 
Median 396 153 426 2.47 1.09 0.42 
75
th 
% 541 255 604 3.42 1.32 0.57 
Maximum 1338 1827 2662 4.23 1.86 1.00 
Mean (SD) 446 (297) 233 (318) 501 (461) 2.57 (0.93) 1.11 (0.39) 0.47 (0.22) 
1
 N = 42; 
2
 N = 40  
 
 
Table 4.8: Correlations between plasma and oral fluid amisulpride concentrations. 





Plasma:GBO Plasma:Oral-Eze GBO:Oral-Eze 
Amisulpride 0.598 * 0.882 * 0.570 * 
Amisulpride excluding 
GBO outlier 
0.867 * - 0.870 * 
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Figure 4-10: Summary patient amisulpride results comparison. 
Box = median and inter-quartile range, whiskers = 95% CI; paired t-test p-value given between each 























Figure 4-11: Plot of amisulpride oral fluid and plasma concentration correlations. 
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4.6.2 Regression analysis 
Regression analyses were undertaken to investigate the relationship between amisulpride oral 
fluid concentrations and plasma amisulpride concentration, age, sex, amisulpride dose, time 
since last dose and the GBO oral fluid content (Table 4.9). As with clozapine, GBO oral fluid 
content was included in the regression the Oral-Eze studies. The difference in plasma 
compared to oral fluid amisulpride concentrations was also investigated to see if there was a 
proportional impact of the plasma concentration on the oral fluid result.  
Unfortunately, due to the smaller number of results obtained for amisulpride, few models 
reached statistical significance. Plasma amisulpride concentration was the only significant 
variable for predicting oral fluid concentrations (Table 4.9); an increase in 100 µg/L plasma 
amisulpride concentration predicted an increase of 51 µg/L and 131 µg/L for GBO and Oral-Eze 
results, respectively. There were no significant variables in predicting the plasma:oral fluid 
concentrations difference for amisulpride, with poor correlation between plasma concentrations 
and the plasma:oral fluid concentration difference (Figure 4-12). 
 
Table 4.9: Regression data for amisulpride concentration prediction. 
























Excluded GBO oral fluid content (p=041), time since dose (p=0.31), sex (p=0.99), age 













Excluded age (p=0.97), dose (p=0.97), GBO oral fluid content (p=0.68), sex (p=0.63), 
time since last dose (p=0.59) 
Difference 
plasma:GBO 
Excluded time since last dose (p=0.99), plasma concentration (p=0.84), sex (p=0.50), 




Excluded GBO oral fluid content (p=0.86), dose (p=0.67), plasma concentration (p=0.80), 
sex (p=0.37), time since last dose (p=0.37), age (p=0.41). 
* model and predictors explained in Section 2.2.2.1 
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Figure 4-12: Plot of difference in plasma:oral fluid concentration and plasma concentration correlations for 
amisulpride.  
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4.7 Other analyte results 
For the other analytes included within the assay, there were insufficient sample numbers to 
undertake statistical investigations, therefore only summaries were reported. 
 
4.7.1 Risperidone 
In total, 10 samples were obtained from 6 patients (one female aged 54, and 5 male aged 
22-33) co-prescribed risperidone. A second sample was received from 4 male patients. Of the 
patients, the dose was stated in 4 cases as oral 3 and 4 mg/d and depot injection of 50 mg in 
two cases. Time since last dose was known in two cases (16 and 18 h). 
Summary results (Figure 4-13) show that the GBO results were significantly different for 
risperidone compared to the plasma and Oral-Eze results, however the Oral-Eze results were 
significantly different to plasma and GBO results for 9-hydroxyrisperidone, and there was no 
significant difference in 9-hydroxyrisperidone MR. 
 
4.7.2 Fluoxetine 
In total, 8 samples were obtained from 4 patients (all male aged 42-57) co-prescribed fluoxetine. 
A second sample was received from each patient. Of the patients, the dose was stated in all 
cases as between 20 and 40 mg/d. Time since last dose was known in two cases (both 24 h). 
Summary results (Figure 4-14) show that the fluoxetine results were significantly different 
between plasma and each oral fluid result, although not between the two oral fluid results. The 
norfluoxetine Oral-Eze results were significantly different to those from plasma and GBO 
samples, and for the norfluoxetine MR there was only significant difference between the GBO 
and Oral-Eze samples. 
 
4.7.3 Olanzapine 
In total, 8 samples were obtained from 4 patients (all male, aged 21-59) co-prescribed 
olanzapine. A second sample was received from 3 patients, and one provided a third sample. 
Of the patients, the dose was stated as between 15 and 30 mg/d, and time since last dose only 
known in one case (12 h). 
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Summary results (Figure 4-15) show there was no significant difference between the plasma 
and GBO concentrations, however difference was significant between Oral-Eze and the other 
matrices since these results were markedly higher. 
 
4.7.4  Quetiapine 
There were only two patients who were co-prescribed quetiapine, both male, aged 50 and 
64 yrs; dosage was not recorded in either case. Full results are given in Table 4.10; no further 
analysis was possible due to the low numbers. With such small numbers, firm conclusions 
cannot be sought, however whilst the MR for 7-hydroxyquetiapine and O-desalkylquetiapine 
look similar between plasma and oral fluid, the MR for N-desalkylquetiapine was approximately 
0.6 for plasma, 1 for GBO and 1.5 for Oral-Eze, suggesting a differing transfer of 













Figure 4-13: Summary patient risperidone, 9-hydroxyriseridone and the metabolic ratio results comparison. 
 (a) risperidone, (b) 9-hydroxyrisperidone, (c) 9-hydroxyrisperidone MR ratio. Box = median and inter-quartile range, whiskers = range; paired t-test p-value given between each 








































































































p = 0.12 p = 0.49












Figure 4-14: Summary patient fluoxetine, norfluoxetine and the metabolic ratio results comparison. 
(a) fluoxetine, (b) norfluoxetine, (c) norfluoxetine MR ratio. Box = median and inter-quartile range, whiskers = range; paired t-test p-value given between each dataset for each analyte. 















































































p = 0.09 p = 0.02
p = 0.08(a) (b) (c)
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Figure 4-15: Summary patient olanzapine results comparison. 
Box = median and inter-quartile range, whiskers = range; paired t-test p-value given between each dataset 








































Plasma 41 19 < 2 4 
GBO 23 23 3 3 
Oral-Eze 28 40 3 3 
Male, 50 
Plasma 22 16 < 2 3 
GBO 12 15 2 2 
Oral-Eze 11 17 2 2 
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4.8 Discussion 
4.8.1 Application of the oral fluid devices and oral fluid content 
There were some reported issues with regards to application of the devices. For the GBO 
device, two patients swallowed the fluid instead of holding it in the mouth. Also the accuracy of 
the 1 mL indicator for the Oral-Eze device was questionable; when the device was used the 
blue line sometimes did not move and the pad had to be removed at 10 minutes, but when 
taken out of the mouth suddenly jumped to higher up the pad. No specific end-of-sampling 
questionnaire was undertaken; were the trial to be repeated this would be something that would 
be of value to undertake. General comments that were reported by the clinical staff were that 
the patients complained about the taste of the GBO collection fluid, but overall that they 
preferred both processes to venepuncture. 
Pre-analytical handling of the GBO samples was simple since the collection system was fully 
self-contained up to the point where the sample enters the laboratory from storage. However, 
tartrazine quantification adds another analytical requirement. As to the Oral-Eze system, the 
need to recover the sample after overnight refrigeration prior to storage added an extra step, but 
laboratory analysis was simplified by collecting a theoretical fixed volume. 
Patient results were corrected for oral fluid volume in the case of the GBO system samples, and 
for recovery from the Oral-Eze system pad. In the case of the GBO system samples the 
average oral fluid content was approximately 50 % (1+1) dilution, but one sample only 
contained 13 % oral fluid (1+8 dilution in collection solution), which would clearly have sensitivity 
implications. Sensitivity was slightly poorer for the Oral-Eze samples due to the dilution (1+2) of 
the calibration solutions performed to reflect the dilution of the samples during sample 
collection, but this did not adversely affect the results. The Oral-Eze system aims to collect 1 mL 
oral fluid, but work with a similar device in which the collection pad was weighed before adding 
to the transport buffer has shown that the actual volume collected can vary dramatically (Patteet 
et al., 2016; Langel et al., 2008). However, this would not be practical in-clinic and we thus 
decided to use the device per the manufacturer’s instructions to test the real-life application of 
the system. 
As to the proportion of oral fluid collected using the GBO system, Haririan et al. (2016) reported 
values of approximately 70 ± 6 % (mean ± SD) in three groups of dental patients. However, a 
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mean (range) oral fluid content of 56 (39–73) % (RSD 15 %) was found in volunteers given 
codeine (Coucke et al., 2016), results much more in keeping with those obtained here, i.e. 
mean (range) of 51 (13–86) %. Moreover, the results from the patients who gave three different 
samples show that even within the same patient there can be a high degree of between 
collection variability in the proportion of oral fluid collected using the GBO system.  
That there would be no residue remaining in the mouth after Oral-Eze sample collection and 
that the oral fluid could become contaminated by the GBO collection fluid was the basis of the 
decision to collect the Oral-Eze specimen before the GBO system specimen. The possibility that 
there was a hangover effect from use of the GBO system was noted by Coucke et al. (2016); in 
a volunteer study, codeine concentrations measured in oral fluid collected with the GBO system 
showed a better correlation with plasma codeine concentrations than in oral fluid collected with 
a pad-based collection device (Quantisal, Alere), particularly when Quantisal was used first. 
However, the correlations were still not good enough to predict plasma codeine reliably from 
oral fluid codeine.  
The medications being investigated within this work have been reported to have some impact 
on salivation rates in patients; clozapine influences salivation in some patients either by 
enhancing saliva production, or via impairing the swallowing reflex. Amisulpride may reduce 
clozapine-induced hypersalivation in some instances (Kerinin et al., 2011). Be this as it may, 
there was no relationship between the volume of oral fluid collected by the GBO system, the 
prescribed dose, and either the plasma, or the GBO and Oral-Eze system oral fluid 
concentrations for any analyte. 
4.8.2 Clozapine results 
The clozapine and norclozapine concentrations in the GBO and Oral-Eze system samples 
correlated poorly with the corresponding plasma concentrations in all cases (Figure 4-2). There 
was also a poor correlation between the analyte concentrations between the two oral fluid 
samples (Figure 4-3). The results from the GBO system samples were significantly lower for 
both clozapine and norclozapine, although the Oral-Eze results were lower for clozapine but 
higher for norclozapine compared to plasma (Figure 4-4, Table 4.3). The norclozapine MR was 
dramatically higher in the Oral-Eze samples compared to plasma and GBO samples. These 
results suggest that the Oral-Eze device collects norclozapine preferentially over clozapine, 
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either as analyte adsorption to the pad, or as an effect of differing transfer of the analytes from 
plasma to saliva and into oral fluid, possibly related to plasma protein binding or analyte pKa. 
Results in oral fluid in 33 samples collected by the drool method showed a poor correlation to 
plasma for both clozapine and norclozapine (Fisher et al., 2013). For the data included herein, 
correlation to plasma for clozapine in both GBO and Oral-Eze sample types was slightly higher 
than for samples collected by the drool method, but the results were comparable or lower for 
norclozapine (Table 4.11). These results were surprising as the theory behind the project was 
that the presence of the buffer in-mouth would minimise the between-patient and between-
collection variability in salivary pH, in turn improving the correlation to plasma. In addition, the 
earlier work using the drool method showed that there was an on-average 3.6-fold higher 
concentration of both clozapine and norclozapine in the plasma than in oral fluid (Table 4.11), 
which was not observed in the devices used in this project where the concentrations were 
around double in the oral fluid from both devices compared to that collected by the drool method 
when looked at as a ratio to plasma. This difference could be due to stimulation of salivary flow 
by the two collection devices which could in turn increase the rate and volume of excretion of 
proteins, electrolytes (Aps and Martens, 2005) and hence increase the flow into saliva of the 
analytes in question. 
Comparison between the concentrations attained in the samples from the two different oral fluid 
devices show that the GBO samples attained concentrations lower than those from the 
Oral-Eze samples when both were corrected for oral fluid content (91 % and 63 % of GBO 
concentrations for clozapine and norclozapine, respectively). 
 
 






Correlation Correlation coefficient (R
2
) 
Plasma:oral fluid analyte 
mean ratio 
Clozapine Norclozapine Clozapine Norclozapine Clozapine Norclozapine 
GBO device 0.78 0.80 0.60 0.63 1.8 1.6 
Oral-Eze 
device 
0.77 0.76 0.59 0.58 1.4 0.9 
Drool 
(Fisher et al., 
2013) 
0.72 0.81 0.53 0.65 3.6 3.6 
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Regression analysis showed that only 60-70 % of the clozapine and norclozapine oral fluid 
concentration variability could be predicted by the variables studied (Table 4.5 and Table 4.6). 
Plasma analyte concentration explained most of the variability within the model, however age 
and clozapine dose were also significant variables, where an increase in age and clozapine 
dose each predicted an increase in the oral fluid concentration. At low plasma analyte 
concentrations, the oral fluid concentration was lower relative to the plasma concentration 
(higher percentage difference plasma:oral fluid concentration; Figure 4-12), which suggests a 
smaller proportion of the plasma analytes are crossing into the oral fluid that could possibly be 
explained by a non-proportional concentration effect of analyte binding to plasma protein. 
The most positive finding was that in one case a patient became non-adherent to the clozapine 
treatment, and that this result was identified not only in the plasma sample, but also in both oral 
fluid samples. The lower sensitivity due to the dilution of the analytes as collected by the oral 
fluid collection devices compared to plasma did not impact the identification and quantification 
of relevant concentrations. 
4.8.3 Amisulpride results 
Amisulpride is poorly (16 %) plasma protein bound (Bergemann et al., 2004), relatively water 
soluble, and less strongly basic than clozapine and thus oral fluid amisulpride concentrations in 
theory should be much less likely to be affected by changes in saliva flow-rate and thus pH 
during sample collection than those of clozapine and norclozapine. It was therefore unexpected 
that the correlations between plasma and oral fluid were as equally poor as those observed for 
clozapine and norclozapine. 
The amisulpride results were particularly interesting in that the average concentration in the 
Oral-Eze samples was over twice that measured in the GBO samples. This despite the fact that 
the Oral-Eze collection time sometimes extended well beyond that expected (up to 10 min), 
suggesting that a greater-than-expected volume of oral fluid had been collected. The reason for 
this discrepancy is unclear.  
4.8.4 Other analytes  
Concentrations of risperidone and 9-hydroxyrisperidone were significantly lower in the GBO oral 
fluid samples than the Oral-Eze oral fluid samples, but the metabolic ratio was not significantly 
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different, suggesting that risperidone and 9-hydroxyrisperidone transfer equally into samples 
collected with the devices. Concentrations of fluoxetine and norfluoxetine were also lower in the 
GBO oral fluid samples that the Oral-Eze samples. However, norfluoxetine MR was also 
significantly different between the two oral fluid samples, which suggests in this case 
norfluoxetine transfer was less than that for fluoxetine into saliva for the GBO device. 
Overall, analyte concentrations were lower in the oral fluid samples collected using the GBO 
device than those using the Oral-Eze device, although not all were significantly lower and the 
degree of difference varied between analytes. This cannot be explained, especially as the GBO 
device would be expected to be a more stimulated collection and therefore theoretically should 
increase the amount of analyte in the oral fluid. One possibility is that a greater amount of 
stimulation increased the proportion of some constituents of oral fluid, such as water, without 
increasing the transfer of analyte from plasma into saliva thereby having a dilution effect. 
Alternatively, it could be due to changes in the salivary pH that occur following simulation (Kato 
et al., 1993). This may explain why the analytes have different ratios between the samples 
collected for the GBO and Oral-Eze collection, since the analytes would transfer differentially 
depending on the physiochemical parameters such as pKa and plasma protein binding. 
4.8.5 Antipsychotic TDM 
Patients prescribed clozapine were studied because they have blood taken routinely for 
haematological monitoring, and thus have a high degree of interaction with mental health 
professionals. In addition, clozapine and norclozapine TDM has proved valuable in assessing 
adherence and guiding dosage. Clozapine and norclozapine are said to be some 95 and 90 % 
bound, respectively, to plasma protein (Schaber et al., 1998), giving examples of moderately-
plasma protein bound analytes. A secondary consideration was that a proportion of patients 
were likely to be co-prescribed amisulpride, which has different physiochemical properties to 
clozapine and this would provide a contrast for comparative purposes. 
The results of this work have shown that there was a difference in the results obtained between 
two different oral fluid collection devices when compared to plasma, even when used side-by-
side, for basic drugs with completely different physicochemical properties. Comparisons of the 
different oral fluid devices in a variety of applications have been published and overall show that 
there is a wide difference between device and between collection technique (Coucke et al., 
2015; Crouch et al., 2008; Langel et al., 2008). The current work parallels the conclusion of one 
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paper stating the importance of fully validating each device and setting up ranges for each 
individual analyte (Langel et al., 2008), since the devices collect and stabilise analytes in 
different ways. The drugs investigated within this study may themselves have an impact of 
salivation, especially clozapine that is known to significantly induce hypersalivation. However, 
amisulpride may ameliorate this impact (Kreinin et al., 1993). No link was found either to 
clozapine dose or clozapine concentrations and the volume of oral fluid collected. 
In addition, there appeared to be considerable differences in the transfer of the analytes from 
plasma to saliva and into oral fluid depending on the collection device used, even with regards 
to parent drugs and metabolites, therefore individual ranges and metabolic ratios would need to 
be identified for each individual collection device prior to application in routine use. 
Concentrations of some of the analytes appeared to decrease with increased salivary 
stimulation, possibly due to salivary pH changes (Kato et al., 1993) or an increase in the 
excretion of water acting to dilute the analytes in the oral fluid collected. 
Overall the correlations observed in the study between plasma and oral fluid concentrations 
collected using both devices were inadequate with regards to predicting plasma concentrations 
for clinical TDM purposes, as has been found in other studies on antipsychotics or similar drugs 
(Flarakos et al., 2004; Horning et al., 1977;  Saracino et al., 2010; Mandrioli et al., 2011; Patteet 
et al., 2015; Patteet et al., 2016). There was also no evidence of the relationship between 
plasma and oral fluid concentrations being affected by patient demographics, prescribed dose, 
or plasma concentration. 
One study investigated the variability in the difference between plasma and oral fluid 
concentrations for eight antidepressants a week apart from one or two patients prescribed each 
of these medications, and found variability high for all drugs, including fluoxetine (de Castro et 
al., 2008). Venlafaxine was the least variable analyte (RSD <27 %), and was studied further in 
five patients. However, the study showed that although variability between samples was low in 
plasma, quantification of the plasma free fraction and in oral fluid remained highly variable (RSD 
up to 70 %), and as such they concluded that oral fluid measurement may only have benefit in 
special circumstances such as to investigate non-adherence. 
Wille et al. (2009) also reported poor correlations between whole blood and oral fluid 
concentrations collected with the Intercept (OraSure) device of a number of common drugs of 
abuse such that reliable calculation of blood concentrations from oral fluid concentrations was 
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simply not possible. Similar findings have been reported using the Saliva-Sampler device 
(StatSure Diagnostic Systems) (Langel et al., 2014).  
Even with lithium ion using a wide range of oral fluid collection techniques there is no 
consensus as to the validity of oral fluid as opposed to serum lithium monitoring (Langman, 
2007; Shetty et al., 2012). Other work using investigating the relationship between plasma and 
oral fluid concentrations of other proteins and drugs have also been equally disappointing as 
regards to predicting analyte plasma concentrations (Coucke et al., 2016; Haririan et al., 2016; 
Kato et al., 1993; Nemecek et al., 2011) 
The fact that similarly poor correlations were found here for clozapine, norclozapine, and most 
surprisingly also for amisulpride, under relatively controlled conditions (stable dosage, tablets 
only, time since last dose at least 10 hours), even using the GBO system where a known oral 
fluid volume in collected under defined oral cavity pH, suggests that applying these devices as 
per the manufacturer’s instructions cannot replace plasma sampling for TDM of antipsychotics. 
This being said, if complete non-adherence is suspected oral fluid analysis may give clinically 
relevant information.  
Further investigation into the variability of analyte recovery from the pad, as discussed in 
Chapter 3, will gather more information into whether the impact of this variable can be 
minimised in future modifications to the device. In addition, whether the use of a pH 7.4-buffered 
in mouth collection system would yield better results can only be speculation at this stage, but 
this may be the next step forward in attempting to develop an oral fluid assay for antipsychotic 
TDM. 
The main positive finding from the present study was that a patient who had become non-
adherent to clozapine was identified by analysis of oral fluid collected using both systems. 
Although non-adherence to clozapine is fortunately quite rare, non-adherence to other drugs 
such as β-blockers is a real clinical problem (Corrêa et al., 2016). However, in contrast to 
testing for either non-adherence to prescribed therapy, or illicit drug use where detection and 
qualitative identification is all that is needed, information to assess possible partial adherence 
and guide dosage is simply not provided by qualitative testing. In conclusion, the results 
emphasise that oral fluid collected using either the GBO system, or the Oral-Eze system cannot 
be used for quantitative TDM of the analytes studied.  
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Chapter 5.  Conclusions 
Therapeutic drug monitoring can be a vital part of optimising drug therapy, and its use in 
treatment with some antipsychotic drugs has been established.  
5.1 Quetiapine metabolite TDM 
TDM is used frequently in assessing adherence to quetiapine, however there is yet to be a 
reference range established for plasma quetiapine concentrations associated with clinical 
response. One possible reason for this is that the plasma half-life of quetiapine is quite short, 
and in addition at least one of the quetiapine metabolites, N-desalkylquetiapine, is believed to 
be pharmacologically active in depression. As such, inclusion of some or all plasma quetiapine 
metabolites in TDM may be necessary for a clinical reference range, or at least to provide 
further information for investigating quetiapine exposure. 
Plasma N-desalkylquetiapine concentrations attained during routine therapy in this study match 
those reported by other studies. In the case of both O-desalkylquetiapine and 
7-hydroxyquetiapine there are no published reports of the plasma concentrations of these 
metabolites attained during routine quetiapine treatment, except for the pilot study of small 
samples numbers (Fisher et al., 2012A). The work presented herein includes many more patient 
samples, and dose-dependent tables for the plasma concentrations of quetiapine and its 
metabolites attained at difference prescribed doses have been presented to aid interpretation of 
future results. 
Investigating the relationships between quetiapine and its metabolites showed that 
O-desalkylquetiapine shows a strong relationship to plasma quetiapine that is not matched by 
either other metabolite. However, 7-hydroxyquetiapine was the only metabolite that showed a 
significant relationship to age. Formulation only affected N-desalkylquetiapine MR and 
O-desalkylquetiapine C/D, whereas sex affected only the C/D for both N-desalkylquetiapine and 
O-desalkylquetiapine. As such, it appears that each metabolite is affected differently through the 
activity of different enzymes and transporters, and investigating plasma concentrations of each 
metabolite alongside quetiapine represents additional information that can benefit in interpreting 
quetiapine results. 
The audit undertaken herein used results from samples sent for routine plasma quetiapine 
TDM, therefore there will have been a variety of reasons why samples were sent for analysis. 
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Thus, the data presented here may include cases of poor adherence to the medication regimes 
and hence the results cannot be taken as plasma concentrations associated with a good clinical 
response and minimal side effects.  
5.2 Oral fluid for antipsychotic TDM 
Use of less invasive sampling procedures may enhance the use of TDM for antipsychotics; 
therefore the role of oral fluid sampling was investigated. A pilot study had compared the 
plasma concentrations attained in patients routinely prescribed these medications to 
concentrations attained in oral fluid collected via the drool method (unstimulated oral fluid; 
Fisher et al., 2012A). The results showed that the relationship between plasma and 
unstimulated oral fluid concentrations were poor for the drugs investigated, including clozapine. 
One possible reason for this poor relationship was the variability in the pH of the oral fluid, as 
contributed to by salivary pH and affected by the degree of stimulation and between-patient 
variability in the resting pH of the oral cavity. Utilising a device that stimulates salivary flow could 
in theory reduce between-patient and between-sample variability in oral fluid pH, and thus could 
improve the relationship between plasma and oral fluid concentrations, and in turn enable oral 
fluid results to be interpreted against the established plasma reference ranges. 
Two oral fluid collection devices were selected to test this theory; the GBO collection system 
which uses a buffered collection fluid held in the mouth that contains a dye from which the total 
volume of oral fluid collected can be calculated, and the Oral-Eze device which uses an 
untreated pad held against the cheek until the indicator shows 1 mL of oral fluid has been 
collected. Holding the pad in the mouth lightly stimulated salivary flow, and post-collection the 
pad is stored in a buffer solution to allow the adsorbed analytes to equilibrate with the buffer, 
before this solution is collected and analysed. Variability in the relationship to plasma 
concentration was consistent between the two oral fluid devices. Concerns were raised 
regarding accuracy of the one mL collection volume for the Oral-Eze device. However, if this 
was inaccurate then it would be suggested that the relationship to plasma should be improved 
for the GBO device for which the volume of oral fluid is accurately calculated. As such, it 
appears that there is an inherent variability in the results that is not reliant purely on the volume 
collected, and not improved by collecting oral fluid when the oral cavity pH is buffered to an 
acidic pH. Reassessment of the variability in analyte adsorption/recovery from the pad to a 
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greater degree according to the proposal discussed in Chapter 3 may shed more light on the 
impact of this variable. 
Both devices stored the collected oral fluid within an acidic buffer and this was shown to 
improve olanzapine stability compared to previous work using unstimulated oral fluid alone, 
where olanzapine was not stable for even a few days (Fisher et al., 2013C).  
Analytical considerations of using the oral fluid collection devices included, for the GBO device, 
the need to quantify the tartrazine dye concentration, and consideration of an observed up to 
1+8 dilution of the oral fluid. For the Oral-Eze samples there was no need for an extra 
quantification step since the device assumes of fixed 1 mL volume collection, however 
consideration needed to be made for the 1+2 dilution of oral fluid into the collection buffer, and it 
was found that the 1 mL indicator did not appear to flow consistently. 
Although there was no formal questionnaire to present patient opinion, it was reported that both 
devices were found to be well tolerated by the patients and preferred to venepuncture, although 
there was some dislike of the taste of the GBO device and confusion over collection process. 
Further investigation into patient preference between devices would be useful in future studies. 
Analysing the 200 sample sets that were collected from patients showed that the correlation 
between the plasma and oral fluid concentrations for clozapine and norclozapine was not 
improved compared to those results from the unstimulated (drool) samples. In addition, there 
was no significant degree of predictability as regards the oral fluid analyte concentrations with 
regards to the variables considered, such as patient demographics and prescribed dose. 
It was found that for many of the medications the analyte concentrations were significantly lower 
in the GBO samples than in the Oral-Eze samples. This was in some ways unexpected since 
the GBO device utilises a buffered liquid held in the mouth which theoretically would trap the 
basic drugs within the acidic fluid, however this observed result could simply be a feature of the 
stimulation of salivary flow. The presence of the citric acid acidic buffer in the mouth would 
stimulate salivary flow, and therefore increase the amount of analyte crossing into the oral fluid. 
However, one possibility is that the increased salivary flow, which is known to affect saliva pH, 
affected the transfer of the analytes from plasma across into saliva and decrease the ratio of 
analyte compared to other salivary components such as water and proteins. Device-specific 
reference ranges may be required due to the analyte-specific variability in samples collected 
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using different oral fluid collection devices. In addition, consideration must be made to ensure 
limits of detection match the dilution applicable to the samples collected using different devices. 
The GBO oral fluid collection device trialled in this study relied upon salivary stimulation from 
holding an acidic buffered solution in the mouth. Using this buffer did not improve the correlation 
of analyte plasma concentrations to the oral fluid concentrations compared to a non-buffered 
lightly stimulating collection device (Oral-Eze). However, analyte-specific variability between the 
results of the two devices was observed. As such, this leaves a possibility that modifying the 
buffer applied may yet improve the correlation. Plasma pH is controlled by homeostasis to 
between pH 7.35 and 7.45, whereas salivary pH is dependent on a number of factors including 
salivary stimulation (whether physical or psychological) that means the pH of the oral cavity is 
so variable. Therefore, whether buffering the oral cavity to match the pH of plasma (~pH 7.4) 
would remove the influence of the degree of stimulation should be tested. 
In one case, a patient prescribed clozapine became non-adherent to the medication regime and 
this was identified not only in the plasma sample, but also in both oral fluid samples. As such, 
whilst the application of oral fluid to interpret TDM against the plasma concentration reference 
ranges will not be possible based on the data presented here, there may be a role of oral fluid in 
special circumstances such as detecting non-adherence, not only to other centrally-acting drugs 
but also to β-blockers, for example (Corrêa et al., 2016). Additionally, changes to the devices or 
collection process as discussed may enable greater reduction in the variability seen. 
5.3 Future opportunities for antipsychotic TDM 
The value of including metabolites within plasma TDM of quetiapine has been illustrated, and 
the dose-dependent metabolite concentrations attained in patients prescribed quetiapine may 
enable better interpretation of future TDM results. Investigation of plasma metabolite 
concentrations attained in patients responding to quetiapine in the treatment of different 
illnesses would enable much greater understanding of the role of quetiapine metabolites in 
quetiapine therapy. This may allow development of a treatment schedule that is personalised to 
the individual based on the diagnosis and measured plasma concentrations, rather than being 
driven purely by recommended dosage regimens. 
This study shows that there is currently no way to use oral fluid collected using the existing 
devices (as presented and following the described procedures) reliably to replace plasma TDM 
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of antipsychotics, and likely of other basic drugs, although there may be specific applications 
where oral fluid sampling could be used. Modifications to the collection procedure, whether 
looking at ways to reduce the variability in analyte recovery from the Oral-Eze pad, introducing a 
different collection process to make the collection more accurate to 1 mL, or changing the pH of 
the buffered in-mouth collection solution to pH 7.4, for example (as discussed in Chapter 4), 
may enable development of oral fluid TDM.  Clinically, the results obtained by oral fluid 
measurements at this stage would not be able to guide dose modifications, although there may 
be a role when investigating non-adherence.  
Options other than oral fluid to reduce the need for venepuncture include using capillary blood 
finger-prick samples and sweat. Recent work has shown that there was significant correlation 
between venous and capillary plasma concentrations of SGAs (Remmerie et al., 2016). 
However, whilst the relationship was significant, as with the oral fluid work presented herein, the 
correlation was not high and there appeared to be large outliers in the data that appeared to be 
at concentrations twice those predicted by the trendline. In addition, the conditions for collection 
of the sample were not thoroughly described, and it may not be possible to replicate the same 
techniques in a real-life clinical environment.  
Application of capillary blood sampling for antipsychotic TDM has the issue that the capillary 
sample will be generally be whole blood rather than plasma, and therefore the analyte whole 
blood:plasma distribution must be taken into account. Capillary blood is not an equivalent matrix 
to venous blood, and in addition during sampling there will likely be contamination from tissue 
fluid and sweat. Applying finger-prick blood to paper to form a dried-blood spot is well 
established in some fields, such as new-born screening. However, the volume collecting and 
spreading of a dried blood spot is affected by many variables including haematocrit and whether 
the finger is squeezed during collection (Enderle et al., 2016). As such, qualitative screening is 
much more suitable to this collection method than quantitative analysis. 
Micro-sampling techniques that collect a fixed volume of finger-prick blood are increasingly 
being used, and have been applied to different fields of TDM including a positive finding for 
hydroxychloroquine (Qu et al., 2017). This was proposed as an advance since it removes the 
limitations of dried-blood spots such as sample inhomogeneity and haematocrit, whilst still 
retaining the advantages such as at-home sampling and reduced sample handling logistics. 
 Page 140 
Other options for alternative matrices include sweat and breath, although in general these have 
qualitative applications. Analysis of sweat relies on knowledge of the transfer of drugs from 
plasma into the sweat ducts and rates of excretion. Sweat analysis is used for analysis of 
chloride content in sweat to diagnose cystic fibrosis, although there are limitations based on 
establishing the sample volume, the rate of excretion and external contamination (Velghe et al., 
2016).  
In general, breath analysis has not been implemented widely, as limitations include logistical 
issues in the storage and collection of exhaled air, although applications include investigation of 
asthma and chronic obstructive pulmonary disease (Velghe et al., 2016). Roadside testing is a 
convenient means of rapid identification of exposure to illicit substances that may impair driving 
performance. Recent UK legislation has imposed blood limits for some commonly abused drugs 
such as amphetamines and cocaine analogous to those in force for blood ethanol (Department 
of Transport, 2013), which can be measured indirectly and non-invasively by use of breath 
ethanol. By extension there is also interest in the use of quantitative measurements of common 
drugs of abuse in oral fluid to obviate the need for venepuncture (Gjerde et al., 2015). However, 
the nature of the sample collection device used may affect limits of detection and, based on the 
work on antipsychotics described here, may not apply a consistent relationship between the 
blood and oral fluid concentrations of common drugs of abuse given that the physicochemical 
properties of all the compounds are so similar. 
With advancements in sampling techniques, there is a risk that analytical methods may not be 
suitable for the increasing requirement for sensitivity and selectivity. Use of LC-MS/MS, as 
shown in Chapter 3, can meet the requirements for identifying many relevant analytes from a 
single sample. The speed at which the results are available and can be acted upon to optimise 
patient therapy is an important aspect of TDM. Advancements have enabled sample extraction 
to be semi-automated (Couchman et al., 2016), and fast-LC techniques have been developed to 
analyse multiple drugs and metabolites within a 1-minute gradient analysis (Couchman et al., 
2017), with the possibility of using isotopic internal calibration to reduce the need for batch-type 
analysis (Couchman et al., 2013). These analytical advancements could enable faster turn-
around-times of the results at lower cost, which in turn could improve the utility of TDM in 
optimising antipsychotic therapy. 
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Appendix A. Ethics letter of approval and protocol for the 
collection of clinical samples 
 
Included herein: 
- Approval notice for ethics (2 pages) 
- Patient information and consent form (4 pages) 
- Sample collection protocol (6 pages) 
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Appendix B. Within- and between-batch IQC results 
 
Included herein: 
- Within- and between-batch IQC replicate results from which to calculate the inaccuracy and 
imprecision for the GBO device method (Tables A-1 and A-2) 
- Within- and between-batch IQC replicate results from which to calculate the inaccuracy and 
imprecision for the Oral-Eze device method (Tables A-3 and A-4) 
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Table A-1: Individual within-batch IQC results for GBO system method. 
 
Nominal [analyte] (µg/L) 
Replicate result (µg/L) 
1 2 3 4 5 
Amisulpride 
6 7 7 6 7 7 
75 65 74 69 69 72 
300 265 279 290 289 289 
Aripiprazole 
6 5 3 4 3 4 
75 32 34 34 34 34 
300 221 215 222 217 214 
Dehydroaripiprazole 
6 4 2 3 3 3 
75 31 32 32 33 32 
300 236 217 220 221 221 
Clozapine 
60 52 50 49 51 52 
300 281 277 271 275 272 
900 860 907 886 834 843 
Norclozapine 
60 53 48 47 50 51 
300 261 277 271 276 277 
900 824 834 836 845 841 
Fluoxetine 
6 7 5 5 6 7 
75 66 86 70 80 78 
300 271 334 333 279 238 
Norfluoxetine 
6 7 5 5 6 7 
75 82 85 77 75 83 
Olanzapine 
3 3 3 3 3 3 
30 25 26 26 25 26 
90 81 76 76 82 80 
Quetiapine 
6 7 6 6 6 7 
75 68 67 65 66 66 
300 277 281 269 276 284 
N-Desalkylquetiapine 
6 8 6 6 7 7 
75 73 66 64 67 68 
300 278 272 289 254 261 
O-Desalkylquetiapine 
3 3 3 3 3 3 
30 32 30 29 30 30 
90 93 92 91 89 91 
7-Hydroxyquetiapine 
3 3 3 3 3 3 
30 29 29 29 31 30 
90 92 88 90 84 90 
Risperidone 
3 3 3 3 3 3 
30 29 28 29 29 30 
90 87 87 90 87 88 
9-Hydroxyrisperidone 
3 4 3 3 3 3 
30 30 29 30 28 28 
90 87 85 93 92 85 
Sulpiride 
6 8 6 7 6 6 
75 84 89 84 82 87 
300 338 323 317 290 320 
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Table A-2: Individual between-batch IQC results for GBO system method. 
 
Nominal [analyte] (µg/L) 
Replicate result (µg/L) 
1 2 3 4 
Amisulpride 
6 7 7 7 7 
75 67 70 72 73 
300 278 282 282 293 
Aripiprazole 
6 2 4 4 3 
75 22 34 30 30 
300 219 218 225 191 
Dehydroaripiprazole 
6 2 3 3 3 
75 21 32 30 33 
300 215 223 238 211 
Clozapine 
60 51 51 49 48 
300 322 275 275 267 
900 872 866 843 823 
Norclozapine 
60 53 50 49 49 
300 287 272 271 261 
900 895 836 845 825 
Fluoxetine 
6 6 6 6 5 
75 88 78 69 65 
300 291 289 294 285 
Norfluoxetine 
6 8 6 7 6 
75 68 80 89 79 
Olanzapine 
3 3 3 3 3 
30 28 26 25 24 
90 83 79 78 74 
Quetiapine 
6 6 7 6 6 
75 67 66 67 65 
300 283 278 271 273 
N-Desalkylquetiapine 
6 6 7 6 6 
75 63 68 68 69 
300 279 271 274 284 
O-Desalkylquetiapine 
3 3 3 3 3 
30 31 30 30 30 
90 88 91 90 91 
7-Hydroxyquetiapine 
3 3 3 3 3 
30 29 29 29 28 
90 110 89 84 85 
Risperidone 
3 3 3 3 3 
30 27 29 28 29 
90 83 88 87 87 
9-Hydroxyrisperidone 
3 3 3 3 3 
30 32 29 28 29 
90 97 88 86 87 
Sulpiride 
6 6 6 7 7 
75 70 93 85 93 
300 336 317 316 335 
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Table A-3: Individual within-batch IQC results for Oral-Eze system method. 
 
Nominal [analyte] (µg/L) 
Replicate result (µg/L) 
1 2 3 4 5 
Amisulpride 
6 7 6 7 7 7 
75 75 72 72 70 74 
300 309 304 293 301 288 
Aripiprazole 
6 11 11 11 11 12 
75 82 90 85 84 86 
300 362 321 341 350 342 
Dehydroaripiprazole 
6 12 12 12 12 12 
75 97 107 104 105 102 
300 430 377 412 397 407 
Clozapine 
60 68 68 71 70 68 
300 299 283 301 281 288 
900 914 935 907 943 924 
Norclozapine 
60 69 67 67 66 70 
300 271 275 258 276 286 
900 883 882 905 945 877 
Fluoxetine 
6 5 8 7 7 6 
75 64 84 60 67 64 
300 326 312 277 279 343 
Norfluoxetine 
6 9 9 9 6 9 
75 87 74 67 79 77 
Olanzapine 
3 4 4 4 4 4 
30 32 34 32 33 31 
90 96 98 98 102 102 
Quetiapine 
6 6 5 6 6 6 
75 56 56 55 53 53 
300 221 233 221 228 221 
N-Desalkylquetiapine 
6 9 8 7 8 8 
75 79 77 80 80 82 
300 363 339 319 335 328 
O-Desalkylquetiapine 
3 3 3 3 3 3 
30 28 30 30 28 29 
90 85 86 84 86 82 
7-Hydroxyquetiapine 
3 3 2 2 3 3 
30 25 25 22 24 25 
90 75 69 65 74 77 
Risperidone 
3 4 3 4 4 4 
30 32 32 31 32 31 
90 93 96 99 104 94 
9-Hydroxyrisperidone 
3 4 3 3 3 3 
30 32 32 30 32 34 
90 105 93 95 97 102 
Sulpiride 
6 8 5 7 7 5 
75 98 88 79 90 79 
300 342 393 318 352 329 
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Table A-4: Individual between-batch IQC results for Oral-Eze system method. 
 
Nominal [analyte] (µg/L) 
Replicate result (µg/L) 
1 2 3 4 
Amisulpride 
6 7 7 7 7 
75 75 76 73 73 
300 303 314 299 303 
Aripiprazole 
6 11 12 11 12 
75 89 94 85 93 
300 350 368 343 367 
Dehydroaripiprazole 
6 11 12 12 12 
75 102 111 103 110 
300 392 430 404 417 
Clozapine 
60 71 73 69 71 
300 295 295 290 280 
900 926 962 925 927 
Norclozapine 
60 70 70 68 58 
300 281 279 273 222 
900 895 895 898 698 
Fluoxetine 
6 7 6 7 7 
75 87 85 69 66 
300 305 335 307 270 
Norfluoxetine 
6 9 10 9 8 
75 79 74 77 60 
Olanzapine 
3 5 5 4 8 
30 31 35 33 36 
90 95 103 99 97 
Quetiapine 
6 7 6 6 6 
75 58 54 55 54 
300 239 224 225 226 
N-Desalkylquetiapine 
6 9 9 8 8 
75 87 91 80 82 
300 353 375 337 358 
O-Desalkylquetiapine 
3 3 3 3 3 
30 27 28 29 23 
90 80 84 85 75 
7-Hydroxyquetiapine 
3 2 3 3 3 
30 26 24 24 24 
90 77 78 72 69 
Risperidone 
3 4 4 4 4 
30 32 33 31 32 
90 95 98 97 96 
9-Hydroxyrisperidone 
3 4 4 3 4 
30 33 33 32 34 
90 97 106 98 115 
Sulpiride 
6 8 7 6 6 
75 82 95 87 97 
300 319 369 347 333 
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Appendix C. Publications 
 
 
Included herein are complete copies of relevant publications produced prior-to or during this 
project: 
- Fisher D.S., Beyer C., van Schalkwyk G., Seedat S., and Flanagan R.J. (2017). 
Measurement of Clozapine, Norclozapine, and Amisulpride in Plasma and in Oral Fluid 
Obtained Using 2 Different Sampling Systems. Ther Drug Monit. 39, 109-117. 
- Fisher D.S., van Schalkwyk G.I., Seedat S., Curran S.R., and Flanagan R.J. (2013A). 
Plasma, oral fluid, and whole-blood distribution of antipsychotics and metabolites in clinical 
samples. Ther Drug Monit. 35, 345-351.  
- Fisher D.S., Partridge S.J., Handley S.A., Couchman L., Morgan P.E., and Flanagan R.J. 
(2013B). LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid 
and haemolysed whole blood. Forensic Sci Int. 229, 145-150.  
- Fisher D.S., Handley S.A., Flanagan R.J., and Taylor D.M. (2012A). Plasma concentrations 
of quetiapine, N-desalkylquetiapine, O-desalkylquetiapine, 7-hydroxyquetiapine, and 
quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors. Ther 
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